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ABSTRACT 
Multiple sclerosis (MS) is a chronic immune-mediated de-myelinating disease of the central 
nervous system in which immune system attacks myelin, a substance produced by mature 
oligodendrocytes that normally surrounds and protects axons, leading to abnormal impulses 
transmission (Wu et al., 2011).  
During their maturation oligodendroglial precursors cells (OPCs) follow a very precise 
differentiation program, finely orchestrated by transcription factors, epigenetic factors and 
microRNAs, a class of small non-coding RNAs involved in post-transcriptional regulation (He 
and Lu, 2013). Any alterations in this program can potentially contribute to dysregulated 
myelination, impaired re-myelination and neurodegenerative conditions, as it happens in 
multiple sclerosis.  
Based on these considerations, the aim of this study was to investigate the potential role of 
miR-125a-3p, a brain enriched miRNA, in the regulation of OPC maturation and to assess 
whether its alteration can contribute to MS pathogenesis or re-myelination failure.  
First, our gene ontology based study showed that several of its predicted target mRNAs are 
involved in glial cell differentiation, myelination, axon ensheathment and oligodendrocyte 
differentiation, suggesting that miR-125a-3p may have a primary role in the regulation of these 
processes. Then, we characterized its expression pattern in the CNS, showing that it is expressed 
in oligodendroglial cells throughout brain development and is progressively up-regulated 
during OPC in vitro differentiation. We also found that the over-expression of this miRNA 
impairs, whereas its silencing promotes oligodendrocyte maturation in vitro, likely acting on 
different targets at multiple levels of the process. 
Interestingly, we observed an up-regulation of miR-125a-3p in two different mouse models of 
toxic demyelination, induced by cuprizone or lysolecithin administration, suggesting that it may 
represent a hallmark of de-myelination. Furthermore, the over-expression of miR-125a-3p in 
the white matter of mice following lysolecithin-induced demyelination maintained 
oligodendrocytes in the NG2-positive precursor stage, in line with the hypothesis of a delay in 
both their maturation and the subsequent re-myelination process.  
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To identify new mechanisms altered by miR-125a-3p during OPC maturation, we performed a 
transcriptomic analysis after its over-expression in OPCs, showing that miR-125a-3p can 
modulate different pathways and processes, such as Wnt-signaling and expression of ECM and 
adhesion molecules. 
Globally, our data suggest that miR-125a-3p could represent a new negative regulator of re-
myelination and that an antago-miRNA specific for this miRNA may help to foster 
oligodendrocyte maturation in diseases characterized by impaired myelin repair. 
The potential importance of miR-125a-3p in MS was also confirmed by the finding that it is up-
regulated in the CSF of MS patients in the active phase of the disease, suggesting that it could 
represent a potential biomarker for the diagnosis or prognosis of different MS phases. 
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RIASSUNTO 
La sclerosi multipla (SM) è una malattia demielinizzante autoimmune del sistema nervoso 
centrale (SNC) in cui il sistema immunitario attacca la mielina, una struttura prodotta dagli 
oligodendrociti maturi che normalmente circonda e protegge gli assoni, portando ad una 
alterata trasmissione degli impulsi nervosi (Wu et al., 2011). 
Durante la loro maturazione, le cellule precursori oligodendrogliali (OPC) seguono un 
programma di differenziamento molto preciso, finemente regolato da fattori di trascrizione, 
fattori epigenetici e microRNA, una classe di piccoli RNA non codificanti coinvolti nella 
regolazione post-trascrizionale (Li and Lu, 2013). Qualsiasi alterazione in questo programma 
può portare a difetti di mielinizzazione e condizioni neurodegenerative, come avviene ad 
esempio nella sclerosi multipla.  
Sulla base di queste considerazioni, lo scopo di questo studio è stato quello di indagare il 
potenziale ruolo di miR-125a-3p, un miRNA espresso ad alti livelli nel SNC, nella regolazione 
della maturazione degli OPC e di valutare se la sua alterazione possa contribuire alla patogenesi 
della SM o ad ostacolare la rimielinizzazione. 
L’analisi in silico basata sulle categorie presenti in Gene Ontology ha mostrato che numerosi 
bersagli predetti di questo miRNA sono coinvolti nel differenziamento degli OPC e nella 
mielinizzazione, suggerendo che miR-125a-3p possa avere un ruolo primario nella regolazione 
di questi processi. Abbiamo quindi caratterizzato il suo profilo di espressione nel SNC, 
dimostrando che esso, durante lo sviluppo, è espresso in cellule oligodendrogliali e che la sua 
espressione aumenta progressivamente durante la maturazione in vitro. Abbiamo anche 
scoperto che l'eccessiva espressione di questo miRNA ostacola, mentre il suo silenziamento 
promuove, il processo di maturazione degli OPC, probabilmente agendo a più livelli e su diversi 
bersagli. 
Valutando l’espressione di miR-125a-3p in due diversi modelli murini di demielinizzazione 
tossica, indotta da somministrazione di cuprizone o lisolecitina, abbiamo riscontrato un 
aumento della sua espressione nella fase di demielinizzazione, suggerendo che tale alterazione 
possa rappresentare un segno distintivo di danno demielinizzante. Abbiamo inoltre dimostrato 
che la sua eccessiva espressione in sostanza bianca di topi, in seguito a demielinizzazione, 
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mantiene gli oligodendrociti nello stadio precursore, in linea con un ritardo della loro 
maturazione e del successivo processo di rimielinizzazione. 
Per identificare nuovi meccanismi alterati da miR-125a-3p durante la maturazione degli OPC, 
abbiamo eseguito un'analisi del trascrittoma in seguito alla sua sovraespressione, dimostrando 
che esso può modulare diversi aspetti dello sviluppo degli OPC, come l'attivazione di specifiche 
vie di segnalazione e l’espressione di molecole di adesione cellulare. 
Globalmente, i nostri dati suggeriscono che l’alterazione di miR-125a-3p potrebbe 
rappresentare un nuovo meccanismo che regola negativamente la rimielinizzazione e che un 
inibitore specifico per questo miRNA potrebbe contribuire a promuovere la maturazione degli 
oligodendrociti in malattie caratterizzate da difetti di rimielinizzazione. 
La potenziale rilevanza di miR-125a-3p nella sclerosi multipla è inoltre supportata 
dall’aumentata espressione riscontrata nel fluido cerebrospinale di pazienti nella fase attiva 
della malattia, suggerendo che esso potrebbe essere un utile biomarcatore per la diagnosi o 
prognosi di questa patologia. 
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1.1 MicroRNAs and post-transcriptional regulation 
MicroRNAs (miRNAs) are small, highly conserved non-coding RNA molecules involved 
in the post-transcriptional regulation of gene expression (Bartel et al., 2004), generated from a 
precursor stem loop (pri-miRNA) through subsequent cleavages and ultimately incorporated 
into RNA-induced silencing complex (RISC) to function as a guide, directing the silencing of 
target mRNAs. MiRNA-mediated post-transcriptional regulation results in gene expression 
repression at both the level of mRNA stability by promoting mRNA degradation and the level 
of translation (at initiation or after) by inhibiting protein translation or degrading the 
polypeptides, through binding complementarily to 3′UTR of the target mRNAs. In postgenomic 
era, the accepted notion is that a single miRNA can regulate hundreds of targets, even if only 
to a mild degree, however, several miRNAs can bind to their target mRNAs and cooperatively 
provide fine-tuning of a single mRNA target expression (Valinezhad Orang et al., 2014). In 
mammals, miRNAs are predicted to control the activity of approximately 30% of all protein-
coding genes, and have been shown to participate in the regulation of almost every cellular 
process investigated so far. As a consequence, changes in their expression has been observed 
in, and may be responsible for, several human pathologies (Filipowicz et al., 2008).  Actually, 
disease-associated miRNAs represent a major focus of clinical research and a new class of 
targets for the miRNA-based novel therapeutic or diagnostic/prognostic biomarkers 
(Rupaimoole et al., 2011). 
1.1.1 Discovery of miRNAs 
MiRNAs were discovered for the first time in the worm Caenorhabditis elegans (Lee et 
al., 1993; Lau et al., 2001), where, it has been shown that lin-4, a gene known to control the 
timing of C. elegans larval development, does not code for a protein but instead produces a 
pair of small RNAs (Lee et al., 1993). The former RNA was 22 nt in length, and the latter 
approximately 61 nt, which was proposed to be the precursor of the shorter one (Lee et al., 
1993). Then, they noticed that these lin-4 RNAs had antisense complementarity to multiple site 
in the 3’UTR of the lin-14 gene and that this pair led to a reduction in the amount of Lin-14 
protein, allowing the transition from cell divisions of the first larval stage to those of the second 
(Lee et al., 1993).  
_______________________________________________________________________________________________INTRODUCTION 
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A second RNA molecule with similar properties was discovered only six years later, known as 
let-7, another gene in the C. elegans heterochronic pathway (Reinhart et al., 2000). This 
molecule of RNA is able to bind the 3’UTR of several genes involved in C. elegans larval 
development, such as lin-14, lin-28, lin-41, lin-42 e daf-12, and promote the transition from 
late-larval to adult cell fates (Reinhart et al., 2000). Because of their common roles in controlling 
the timing of developmental transitions, the lin-4 and let-7 RNAs were entitled small temporal 
RNAs (stRNAs), supposing that other RNAs with similar functions would be discovered 
(Pasquinelli et al., 2000). Indeed, less than one year later, three labs cloned small RNAs from 
flies, worms, and human cells reporting more than one hundred additional genes for tiny 
noncoding RNAs, approximately 20 new genes in Drosophila, 30 in human, and 60 in worms 
(Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). These RNAs were, similar 
to lin-4 and let-7, expressed endogenously and approximately 22 nt in length, but, since only 
few of them had a role in the temporal development, the term “microRNA” was used to refer 
to the stRNAs and all the other tiny RNAs with similar features but unknown functions (Lagos-
Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). Several studies in the following 
years allowed to identify additional miRNA genes in mammals, fish, worms and flies, and a 
specific database was created to facilitate the naming of newly identified genes (Griffiths-Jones 
2004). Most of miRNAs, such as lin-4 e let-7, of C. elegans, come from regions of the genome 
quite distant from previously annotated genes, suggesting that they had independent 
transcription units (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). 
Nevertheless, about a quarter of human miRNAs are in intronic regions, suggesting that their 
expression is not under the control of a specific promoter, but it is dependent by the processing 
of the related mRNA (Aravin et al., 2003). The miRNAs within a genomic cluster are often related 
to each other, share functional relationship, and related miRNAs are sometimes, but not always, 
clustered. Nearly all the cloned miRNAs are conserved in closely related animals, such as human 
and mouse or C. elegans and C. briggsae (Lagos-Quintana et al., 2001; Lau et al., 2001). 
1.1.2 MiRNA biogenesis pathways 
Like for coding mRNAs, miRNA transcription is carried out by RNA Pol II and is 
controlled by RNA Pol II‑associated transcription factors and epigenetic regulators (Lee et al., 
_______________________________________________________________________________________________INTRODUCTION 
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2004), whereas only some endogenous miRNA-like small RNAs (derived from tRNAs) are 
transcribed by RNA Pol III (Babiarz et al., 2008). The canonical mammalian miRNA processing 
pathway (Figure 1.1) is composed by a series of biochemical steps that convert primary miRNA 
transcripts (pri-miRNAs) into biologically active, mature miRNAs (Kim et al., 2005). 
Pri-miRNA is long (typically over 1kb) and contains a local stem–loop structure, in which mature 
miRNAs sequences are embedded. A typical pri-miRNA consists of a stem of 33-35 bp, a 
terminal loop and single-stranded RNA segments at both the 5ʹ and 3ʹ sides. The nuclear 
RNase III-type endonuclease Drosha initiates the maturation process by cropping the stem–
loop to release a small hairpin-shaped RNA of ~65 nucleotides in length (pre-miRNA). Together 
with its essential cofactor DGCR8, Drosha forms a complex called Microprocessor (Han et al., 
2006). In particular, Drosha liberates the stem-loop pre-miRNAs from pri-miRNAs in 
cooperation with DGCR8-mediated recognition of the junctional region between the single-
stranded and double-stranded portions of pri-miRNAs. The Drosha complex also contains 
several auxiliary factors such as EWSR1, FUS, numerous heterogeneous nuclear 
ribonucleoproteins (hnRNPs), p68 and p72 DEAD-box helicases (Gregory et al., 2004).  
A recent report showed that additional sequence elements are involved in pri-miRNA 
processing (Auyeung et al., 2013). These elements reside in the basal region (the UG motif and 
the CNNC motif) and terminal loop (the UGUG motif) of human pri-miRNAs. At least one of 
these three motifs is present in 79% of human miRNAs, suggesting the relevance of these 
elements. Indeed, it has recently been reported that the CNNC motif is also required for DEAD-
box RNA helicase p72 binding, which increases processing by Drosha (Mori et al., 2014).  
Drosha-mediated processing of intronic miRNAs does not affect splicing of the host pre-mRNA. 
Accordingly, cleavage of pri-miRNAs is thought to occur co‑transcriptionally before splicing 
catalysis (Kim et al., 2007). Otherwise, when a miRNA hairpin is located in the exonic region, 
Drosha-mediated cleavage leads to destabilization of the host mRNA (Han et al., 2009). To 
assure the correct expression level, activity and specificity of Drosha, this important step is 
under the control of an auto-feedback mechanism; indeed, DGCR8 stabilizes Drosha through 
protein–protein interactions, whereas Drosha destabilizes DGCR8 mRNA by cleaving it at a 
hairpin in the second exon (Han et al., 2009). This cross-regulatory loop enables the homeostatic 
_______________________________________________________________________________________________INTRODUCTION 
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maintenance of Microprocessor activity and is deeply conserved throughout the animal 
kingdom. 
 
Figure 1.1 miRNA biogenesis by canonical and non-canonical mirtron pathways and mechanism of 
action (modified by Dai et al., 2011). 
Following Drosha processing, pre-miRNA is exported into the cytoplasm to complete the 
maturation process. The translocation is mediated by the protein exportin 5 (EXP5) that forms 
a transport complex with GTP-binding nuclear protein RAN-GTP and a pre-miRNA. After 
translocation through the nuclear pore complex, GTP is hydrolyzed and the pre-miRNA is 
released into the cytosol (Lund et al., 2004), where the second-round ribonuclease reaction 
takes place. This step is mediated by another important RNase III-type endonuclease, Dicer, 
that, in association to other double stranded RNA binding proteins (dsRBP), dices the pre-
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miRNAs into a 22 nt long miRNA duplex. Dicer binds to pre-miRNA with a preference for a two-
nucleotide-long 3ʹ overhang that was initially generated by Drosha (Zhang et al., 2004). Dicer 
cleavage sites are located at a fixed distance from the 3ʹ end of the terminus of double-strand 
RNAs (dsRNAs, “the 3ʹ‑counting rule”). This distance is typically 21–25 nucleotides in length and 
depends on the species and the type of Dicer (Macrae et al., 2006). In mammals and flies there 
is an additional mechanism to determine the cleavage site of pre-miRNA (“the 5ʹ‑counting 
rule”). In this case, Dicer binds to the 5ʹ phosphorylated end of the pre-miRNA and cleaves it 
22 nucleotides away from the 5ʹ end (Park et al., 2011). Human Dicer1 mRNA contains binding 
sites for let‑7, which results in a negative feedback loop between Dicer and its product let‑7. 
This regulation is thought to contribute to the homeostatic regulation of Dicer activity 
(Tokumaru et al., 2008).  
Small RNA duplex generated by Dicer are subsequently loaded onto an AGO protein to form 
an effector complex called RNA-induced silencing complex (RISC) (Hammond et al., 2001). 
Among the four AGO proteins in humans (AGO1–4), only AGO2 can slice perfectly matched 
target mRNAs. All human AGO proteins can induce translational repression and decay of target 
mRNAs (Huntzinger et al., 2011). Following miRNA duplex loading, the pre-RISC (in which AGO 
proteins associate with RNA duplexes) quickly removes the passenger strand to generate the 
mature RISC. The guide strand is determined during the AGO loading step, mainly based on 
the relative thermodynamic stability of the two ends of the small RNA duplex (Khvorova et al., 
2003) whereas the released passenger strand is quickly degraded. Since the strand selection is 
not completely stringent, the strand that theoretically is not favored can also be selected, as 
guide strand, with varying frequency. The less abundant miRNA is also active and can targets 
different mRNA (Almeida et al., 2012). Alternative strand selection (‘arm switching’) has been 
observed in studies comparing miRNA isoforms in multiple tissues (Chiang et al., 2010). These 
events may be at least partially explained by alternative Drosha processing, which changes the 
relative thermodynamic stability of the miRNA duplex ends (Wu et al., 2009). 
Apart from the canonical miRNA biogenesis pathways, various alternative mechanisms 
can generate miRNAs. One example is the mirtron pathway, in which pre-miRNAs are generated 
_______________________________________________________________________________________________INTRODUCTION 
11 
 
by splicing and debranching of short hairpin introns, termed mirtrons, bypassing Drosha 
cleavage (Ruby et al., 2007; Okamura et al., 2007). 
In addition, some small RNAs may originate from other non-coding RNAs, such as tRNAs or 
tRNA-like precursors, small nucleolar RNAs (snoRNAs), without Drosha processing (Lee et al., 
2009). The existence of non-canonical pathways reflects the evolutionary flexibility of miRNA 
biogenesis. However, the vast majority of functional miRNAs follow the canonical pathway for 
their biogenesis, and only about 1% of conserved miRNAs are produced independently of Dicer 
or Drosha in vertebrates. 
1.1.3 Nomenclature and target recognition 
MiRNA genes constitute one of the most abundant gene families and are widely 
distributed in all species (Griffiths-Jones, 2008). The latest release of the miRNA database 
(miRbase 21) has catalogued 434 miRNAs in C. elegans, 466 miRNAs in Drosophila 
melanogaster and 2,588 miRNAs in humans, although the functional role of many of these 
miRNAs remains to be determined (Kozomara and Griffiths-Jones, 2014). 
In many species there are multiple miRNA loci with very similar sequences that resulted mainly 
from gene duplication. miRNAs with identical sequences at nucleotides 2–8 of the mature 
miRNA belong to the same ‘miRNA family’ (Bartel, 2009) and usually act redundantly on target 
mRNAs, but distinct roles have also been observed (Ventura et al., 2008). Some miRNAs can 
also have a common evolutionary origin but some differences in the seed sequence. For 
example, miR-141 and miR-200 differ by only one nucleotide in their miRNA seeds, but this 
difference leads to a poor overlap in their target mRNAs, emphasizing the importance of the 
miRNA seed sequence in miRNA function and evolution (Kim et al., 2013).   
The current nomenclature of miRNA genes provides that new miRNAs, identified by cloning or 
sequencing, receive a sequential numerical name (e.g., the lin‑4 homologues in other species 
are called mir‑125). Genes encoding paralog miRNAs, that differ for 1-2 nucleotides, are 
indicated with lettered suffixes (e.g., mir‑125a and mir‑125b). In the case that multiple separate 
loci give rise to the same miRNA, an extra numerical suffix is added at the end of the names of 
miRNA loci (e.g., mir‑125b‑1 and mir‑125b‑2). Each locus produces two mature miRNAs: one 
from the 5ʹ strand and one from the 3ʹ strand of the precursor (e.g., miR‑125a‑5p and 
_______________________________________________________________________________________________INTRODUCTION 
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miR‑125a‑3p). It is possible that one arm (the guide strand) is more prevalent and active, but it 
has also been shown that both arms can be biologically active, sharing the same target or not 
(Huang et al., 2014; Choo et al., 2014). In mammals, most of miRNA-mRNA interactions are 
characterized by imperfect complementarity (Bartel et al., 2009), whereas perfect matches are 
very rare (Yekta et al., 2004). 
MiRNA targets commonly have at least one region that has Watson-Crick pairing to the 
5′ part of miRNA located at positions 2-7 from the 5′ end, known as the ‘seed’ (Rajewsky et al., 
2004). Canonical stringent-seed sites have perfect Watson-Crick pairing and can be divided into 
four ‘seed’ types, - 7mer-A1, 7mer-m8, 8mer and 6mer - depending on the combination of the 
nucleotide of position 1 and pairing at position 8 (see Figure 1.2). 7mer-A1 has an adenine at 
position 1, while 7mer-m8 has base pairing at position 8. 8mer has both an adenine at position 
1 of the target site and base pairing at position 8, whereas 6mer have neither an adenine at 
position 1 nor base pairing at position 8 and are considered marginal seed sites since usually 
have reduced efficacy. (Bartel et al., 2009). In addition to this canonical seed matching, 
moderate-stringent seed matching can be also functional because RISC can tolerate small 
mismatches or G:U wobble pairing within the seed region (Martin et al., 2014). 
Watson-Crick pairing in the 3′ part of miRNA is known to enhance the site recognition efficacy 
(Grimson et al., 2007). The required number of matches in the 3′ part differs between the site 
that has stringent seed pairing and the one that has moderate-stringent-seed pairing. 
Stringent-seeds require 3-4 matches in the positions 13-16, whereas moderate-stringent-seeds 
require 4-5 matches in the positions 13-19. Sites with this additional 3′ pairing are called 3′-
supplementary and 3′-compensatory sites (Bartel et al., 2009).  
Several studies have reported that most target sites are in the 3′ UTR segment of target mRNAs, 
despite miRNA-loaded RISC in theory can bind any segment of the transcript. Target genes 
tend to have longer 3′ UTR, whereas ubiquitously expressed genes usually have shorter 3′ UTR, 
potentially to avoid being regulated by miRNAs (Stark et al., 2005). Although functional miRNA 
sites are preferentially located in 3′ UTR, seed sites in the coding sequence (CDS) and 5′ UTR 
regions can also mediate miRNA interaction, leading to functional regulation (Lewis et al., 2005; 
Miranda et al., 2006).  
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An extremely high number of potential target sites exists for any given miRNA and 
computational approach to their prediction can facilitate the selection process for the 
successive experimental validation. 
 
 
Figure. 1.2 Types of miRNA target sites. A-C canonical sites; D-E marginal sites; F 3’-supplementary site; 
G 3’-compensatory site. Modified by Bartel et al., 2009. 
The available tools for miRNA target prediction encompass a range of different computational 
approaches, but commonly they take into account key aspects of the miRNA-mRNA interaction, 
such as site accessibility, seed match, conservation and free energy (Peterson et al., 2014).  
1.1.4 Mechanisms of miRNA-mediated gene regulation 
The biological outcome of miRNA-mRNA interaction can be altered by several factors 
that can influence the binding strength and repressive effect of a potential target site (see 
Figure 1.3) (Carroll et al., 2014). The most crucial factor is a perfect base pairing between the 
miRNA seed region and target site. Other factors include the number of target sites for the 
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same miRNA and their relative position, site accessibility, sequences flanking miRNA target site, 
and their context, and RNA secondary structure can influence the consequences of 
hybridization (Ohler et al., 2004; Majoros et al., 2007; Brodersen et al., 2009). 
Several studies reported that mRNA degradation can be induced either by decapping or 
deadenylation. Missing poly(A) tail and cap structure can be subjected to the 3’-5’ degradation 
by cytoplasmic exonucleases (Hausser et al., 2009; Rehwinkel et al., 2005). Alternatively, 
polysomal ribonuclease 1 (PMR1) can also mediate sequence specific mRNA endonucleolytic 
cleavage in parallel (Bagga et al., 2005).  
 
Figure. 1.3 Principal mechanisms of miRNA-mediated downregulation (modified by Orang et al., 2014). 
However, several publications have shown that in several cases miRNAs do not promote 
degradation of their target mRNAs, but inhibit the conversion into protein by preventing the 
initiation or elongation step of translation (Mathonnet et al., 2007; Pillai et al., 2004). It has been 
shown that AGO protein can interact with several translation initiation factors, such as eIF4E, 
eIF4G or eIF4A, and compete for binding to cap structure (Eulalio et al., 2008).  
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Another possible mechanism of translation initiation block is the Ago interference with the 
formation of closed-loop mRNAs, normally achieved through interaction between cytoplasmic 
poly(A) binding protein and cytoplasmic cap binding protein (Eulalio et al., 2008). Several 
inhibitory mechanisms can also influence the postinitiation or cotranslation steps, leading to 
ribosome dissociation and/or premature termination (Mathonnet et al., 2007; Chendrimada et 
al., 2007) and cotranslational protein degradation by proteases recruitment (Pillai et al., 2007). 
It has been indicated that processing cytoplasmic foci, mostly known as “P bodies,” have a 
central role in mRNA degradation and translation inhibition and it has been proposed that 
miRNAs can repress translation and promote decay by recruiting P body components to specific 
target mRNAs (Sen and Blau, 2005).  
1.1.5 Role of miRNAs in the diagnosis and pathogenesis of human diseases 
As discovery of human miRNAs increased, the research focus was gradually shifted to 
the functional characterization of miRNAs, particularly in the context of human diseases. The 
connection between miRNAs and human disorders was obvious since, in many cases, they 
define the physiological nature of the cell, influencing several vital biological processes, such as 
cell division and death (Ng et al., 2012), cellular metabolism (Rayner et al., 2011), intracellular 
signaling (Zhang et al., 2012), immunity (Taganov et al., 2006) and cell movement (Png et al., 
2012). Therefore, aberrant miRNA expression should have a strong impact on these critical 
processes, thus leading to various pathological and malignant outcomes. In this context 
miRNAs are emerging either as useful tools for the diagnosis and as a new promising category 
of druggable targets (see Figure 1.4). 
Since the early stages of miRNA research, cancer has been the most prominent human 
disease with a clear association to miRNA dysregulation. The first evidence came from a study 
by Calin et al. in which they demonstrated a frequent deletion of miRNA genes miR-15a and 
miR-16-1 in B-cell chronic lymphocytic leukemia (B-CLL) patients (Calin et al., 2002). Since that 
discovery, many studies were directed into characterizing the expression profile of miRNAs in 
different tumors. To date, high-throughput miRNA expression profile analysis has been 
conducted in various human cancers, including glioblastoma, breast cancer, thyroid papillary 
carcinoma, lung cancer, hepatocellular carcinoma, pancreatic cancer, and colon cancer (Calin et 
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al., 2006; Esquela-Kerscher et al., 2006; Spizzo et al., 2009). This studies also showed that miRNA 
profiles of tumor cells are significantly different from normal cells (Calin et al., 2005) and that 
tumors of similar origins have common alterations, providing a tool for cancer diagnosis and 
prognosis (Yanaihara et al., 2006). 
In cancer research, miRNAs were divided in two different categories: miRNAs that act as 
oncogenes and miRNAs that act as tumor suppressor genes. It is worth to note that the same 
miRNA acting like an oncogene in one type of cells can act like a suppressor in another, due to 
different targets and mechanisms of action. For example, miR-125b has been shown a tumor-
suppressor function in hepatocellular carcinoma targeting the oncogene LIN282B (Liang et al., 
2010), but an oncogene function in prostate cancer suppressing the pro-apoptotic gene Bak1 
(Shi et al., 2007). 
 
Figure 1.4 The road from laboratory to clinic: the promises and challenges of miRNA research (modified 
by Li and Kowdley, 2012) 
As a consequence, miRNA therapeutics is aimed to downregulate the function of oncogenic 
miRNAs or to restore the expression of miRNAs that have a tumor-suppressive function. There 
are two main strategies to target miRNA expression in cancer, which include direct strategies, 
involving the use of oligonucleotides or virus-based constructs to block the expression of an 
oncogenic miRNA or to substitute for the loss of expression of a tumor suppressor miRNA and 
indirect strategies involving the use of drugs to modulate miRNA expression (Giza et al., 2014). 
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Alteration of miRNA homeostasis has been also correlated to neurodegenerative 
diseases (NDs), a group of late onset progressive disorders of the nervous system, characterized 
by a complex pathogenesis (Bicchi et al., 2013). Alteration of miRNA levels were associated to 
numerous pathological processes that can contribute to neurodegeneration in Alzheimer’s (AD) 
and Parkinson’s (PD) disease (See Table 1.1), such as response to oxidative stress, cell cycle 
disorders, neuroinflammation, clearance of pathological proteins and cholesterol trafficking. 
For example, several studies reported that miRNAs can modulate the expression of APP 
(Amyloid Precursor Protein), a key protein involved in AD etiopathogenesis responsible for β-
amyloid (Aβ42) accumulation. APP can be proteolyzed directly by α-secretase and then γ-
secretase, a process that does not generate Aβ42, or reinternalized into another endosomal 
compartment containing the β-secretase BACE1 and γ-secretase, leading to the pathological 
accumulation of Aβ42 (O’Brien et al., 2011). According to Liu et al., production of APP protein 
is under the control of miR-193b. Furthermore, they measured the concentration of Aβ42 and 
the expression of exosomal miR-193b in the cerebrospinal fluid, and confirmed a negative 
correlation between these biomarkers (Liu et al., 2014). Several studies have shown that also 
the protease BACE1 is regulated by several miRNAs, such as miR-107, miR-195 and miR-339-
5p and that their over-expression can reduce the expression of BACE1 mRNA and Aβ42 
accumulation (Zhu et al., 2012). Another study from Augustin et al., suggested that also the 
expression of alfa-secretase ADAM10 is regulated by 2 specific miRNAs, namely miR-107 and 
miR-103 (Augustin et al., 2012). These findings were confirmed by another study where a RT-
qPCR approach was used to show that miR-107 and miR-103 were down-regulated in the 
peripheral blood of both AD, PD and schizophrenic patients (Leidinger et al., 2013). 
Several miRNAs were also linked to PD pathogenesis, a neurodegenerative disease 
characterized by loss of dopaminergic neurons that is due, at least in part, by the presence of 
intracellular inclusions, namely Lewy bodies, whose main component is α-synuclein (ASN) (Liu 
et al., 2012). This process may be promoted by mutations in parkin and α-synuclein genes as 
well as in leucine-rich repeat kinase 2 (LRRK2) but, it has recently been shown that the 
metabolism of ASN may also be “fine-tuned” by various miRNAs. For example, it has been 
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shown that miR-7 cooperates with miR-153 to control the quantity of ASN produced, both in 
the adult brain and during neuronal development (Doxakis et al., 2010).  
 
 
Table 1.1 List of miRNAs associated to Alzheimer’s and Parkinson’s diseases reporting the source and 
the type of alteration (Prendecki M and Dorszewska J. Austin Alzheimers J Parkinsons Dis. 2014). 
Moreover, several studies identified miRNA specifically reduced in post mortem brains of PD 
patients, such as miR-34b and miR-34c, showing a negative correlation with the expression of 
Park-7 and Parkin, two proteins associated to familial and sporadic forms of PD (Miñones-
Moyano et al., 2011). 
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As very stable, independent, small genetic entities that are enriched in brain cell cytoplasm, 
cerebrospinal fluid and in peripheral blood, miRNAs may serve as useful biomarkers for the 
early diagnosis of human NDs. Leidinger et al. investigated the blood samples of 44 AD patients, 
finding 140 unique mature miRNAs whose expression levels were significantly altered and 
subsequently, they developed an assay of 12 blood-based biomarkers able to discriminate AD 
cases from controls with an accuracy of 93%, a specificity of 95% and a sensitivity of 92%. They 
also showed that miR-107 decreases most significantly in AD and, on the other hand, it was 
over-expressed in Mild Cognitive Impairment (MCI) (Leidinger et al., 2013). Another 
independent report showed that miR-107 levels were significantly down-regulated in the brains 
of AD patients at a very early stage of the disease suggesting that testing for miR-107 might 
provide useful information about a patient’s condition in the pre-symptomatic stage of 
dementia (Wang et al., 2008). Sheinerman et al. recently identified two miRNA family (miR-132 
and miR-134) for early detection of MCI from plasma sample by using RT-qPCR. The miR-132 
family biomarkers demonstrated 84%-94% sensitivity and 96%-98% specificity, and the miR-
134 family biomarkers showed 74%-88% sensitivity and 80-92% specificity (Sheinerman et al., 
2013). 
Recently, several studies showed that miRNAs play an essential role in the regulation of 
both innate and adaptive immune responses (Figure 1.5). Thus, it is not surprising that several 
miRNAs are tightly related to autoimmune inflammatory diseases, a category of disorder that 
includes many systemic and organ-specific autoimmune diseases (AIDs), such as systemic lupus 
erythematosus, multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus and Crohn’s 
disease. The cause of these diseases is a negative reaction of the immune system to self-tissues 
that leads to the formation of autoreactive cells and autoantibodies and to the production of a 
wide range of pro-inflammatory cytokines and mediators (Baulina et al., 2016). It has been 
shown that specific miRNAs expressed by cells of the immune system and resident cells of 
tissues can repress the synthesis of these important mediators, thereby contributing to the 
development of the autoimmune inflammatory response. The sequential activation of specific 
miRNAs can control the strength level and duration of the inflammatory response induced by 
activation of toll-like receptors (TLR). For example, induction of miR-155 and repression of miR-
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125b and let-7i caused by activation of TLR receptors were shown to promote the production 
of various pro-inflammatory cytokines and activation of an adaptive immune response. 
Whereas miR-21 and miR-147, that are involved in the activation of the inflammatory response, 
inhibit the synthesis of miR-155 and proinflammatory cytokines (O’Neill et al., 2011). It has also 
been demonstrated that miRNAs are actively involved in the regulation of the development 
and differentiation of T and B cells. Indeed, lack of miRNA biogenesis (by Dicer or Drosha 
mutations) leads to a reduced amount of thymocytes, disruption of B and CD4+ cells 
differentiation and early development of autoimmune diseases (Koralov et al., 2008; O’Carroll 
et al., 2007). 
 
Figure 1.5 Role of miRNAs in autoimmune inflammation (Paulina et al., 2016). 
As previously mentioned, the production of several key cytokines is directly regulated by 
miRNAs. For example, miR-29 in T lymphocytes can bind to IFN-γ mRNA and inhibit its 
production (Baumjohann et al., 2013), while miR-23b, expressed in resident fibroblast-like 
synoviocytes, can inhibit NF-κB activation in response to inflammatory cytokines (Zhu et al., 
2012). MiRNAs can also be involved in the recruitment of additional inflammatory cells with 
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participation of chemokines. It was demonstrated that down-regulation of miR-125a causes 
increase of chemokine RANTES (CCL5) production in activated T cells upon development of 
systemic lupus erythematosus (Zhao et al., 2010b), and that increased miRNA-146a expression 
inhibits secretion of chemokines CCL5 and IL-8 in epithelial cells of the human lung (Perry et 
al., 2008). Moreover, a comparative study of miRNA expression in inflammatory lesions in 
patients with rheumatoid arthritis, systemic lupus erythematosus, and MS revealed common 
alterations: expression of miR-23b and miR-30a-5p was enhanced, and expression of miR-214 
and miR-146a was reduced (Zhu et al., 2012). 
1.1.6 Role of the miR-125 family in neural development and disease 
Among the most important miRNA families, miR-125 family (composed by three 
homologs hsa-miR-125a, hsa-miR-125b-1 and hsa-miR-125-2) has been reported to be 
implicated in a variety of carcinomas as either repressors or promoters (Sun et al., 2013). 
Despite this consolidated role in carcinogenesis, in the last years several studies have also 
explored the role of miR-125 family members in the context of central nervous system 
development. MiR-125a and miR-125b were first reported as brain-enriched miRNAs by 
Sempere and colleagues, which performed an expression profiling of mammalian miRNAs in 
murine and human brain (Sempere et al., 2004), suggesting a possible role for miR-125 family 
in neuronal differentiation. Indeed, some years later, it has been shown that over-expression of 
miR-125b promotes neurite outgrowth and that the physiological up-regulation of miR-125b 
during neurogenesis is required to repress a subset of genes that normally inhibit multiple 
pathways involved in neuronal differentiation (Le et al., 2009). Other independent studies 
reported that miR-125a and miR-125b are able to induce neural commitment and neuronal 
differentiation by targeting SMAD4 and Nestin (Cui et al., 2012; Boissart et al., 2012). 
MiR-125a and miR-125b expression was also linked to astrocyte proliferation and 
differentiation. In particular, it has been shown that miR-125a and miR-125b expression 
increase during astrocyte differentiation and that their ectopic over-expression inhibits the 
proliferation of the relative neural precursors by targeting Musashi1 mRNA (Gioia et al., 2014). 
Moreover, it has been shown that miR-125a and miR-125b (together with let-7) can 
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downregulate a common network of targets and cooperate with signaling pathways (such as 
JAK/STAT) to prime progenitor cells for astroglial differentiation (Shenoy et al., 2015). 
MiR-125 family members were also studied in pathological conditions, such as West Nile virus 
(WNV) neuropathogenesis and glioblastoma multiforme (GBM). In particular, it has been 
demonstrated that miR-125a-3p may play an important role in regulating anti-viral cytokines 
in the brain following WNV infection and in the regulation of host immune responses by 
targeting PTGS2, IL1R1, IL10 and CCL4 (Kumar et al., 2014). miR-125a (and also miR-125b) has 
been previously demonstrated to constitutively activate NF-κB pathway (Kim et al., 2012), thus, 
the down-regulation of miR-125a-3p observed after WNV infection could control WNV-
induced inflammation by regulating the activation of NF-κB, and represent a sort of protective 
host response (Kumar t al., 2014). Interestingly, it has been shown that the axis miR-125b/A20/ 
NF-κB can also have a deleterious effect and be responsible for sustained NF-κB activity in 
amyotrophic lateral sclerosis (ALS) microglia and toxicity towards motoneurons (MNs). 
Several independent reports confirmed the implication of miR-125a also in GBM pathogenesis. 
The results of these studies showed that the expression of miR-125a-3p is significantly 
decreased in most malignant glioma and that ectopic over-expression of miR-125a markedly 
induces the apoptosis and suppresses the proliferation and migration of GBM cell lines by 
directly targeting Podoplanin (PDPN), Neuregulin1 (NRG1) and TAZ (Cortez et al., 2010; Yuan 
et al., 2015; Yin et al., 2015).  
 
1.2 Oligodendrogliogenesis and myelination  
In the central nervous system, the impulse transmission and the neural network integrity 
are guaranteed from the activity of specialized glial cells, known as oligodendrocytes. The main 
function of these cells is to produce a fatty substance called myelin (mainly composed by 
glycosphingolipids and cholesterol) and to surround axons with myelin layers, ensuring their 
insulation and the saltatory conduction of nerve impulses. Oligodendrocytes are also implicated 
in the development and survival of neurons and they are also able to form synapses and actively 
participate to the CNS activity (Simons et al., 2015). 
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Oligodendrocytes derived from pluripotent neuroepithelial cells of the neural tube, embryonic 
precursors that can migrate and proliferate. After reaching their destination, they leave the cell 
cycle and acquire a post-mitotic mature phenotype and start to produce myelin proteins and 
lipids (Hu et al., 2009). Oligodendrocyte maturation is under the control of different 
mechanisms, which include extrinsic factors, such as extracellular molecules and other neural 
cells, and intrinsic factors, such as transcription factors and epigenetic modulators. 
1.2.1 Oligodendrocyte maturation and stage-specific markers 
During oligodendrocyte development, differentiation stages can be identified based on 
the expression of specific markers, the increase in morphologic complexity and the migratory 
capacity (Barateiro et al., 2014). Oligodendrocyte maturation can be divided into four different 
stages: oligodendrocyte precursor cells (OPC), pre-oligodendrocytes, immature (or pre-
myelinating) oligodendrocytes and mature (or myelinating) oligodendrocytes (Figure 1.6) 
(Fumagalli et al., 2015). 
OPCs are proliferative cells with a high migratory capacity that specifically express platelet-
derived growth factor receptor α (PDGFRα), proteoglycan NG2, ganglioside A2B5 and 
ganglioside GD3.  NG2 positive precursors can have different morphologies depending on their 
location in the brain, but usually they are characterized by a small polygonal soma and a 
multipolar tree of fine processes. Nevertheless, some studies showed that in white matter they 
can present a bipolar morphology, characteristic of neural precursor cells, with only a few short 
processes send out from the opposing poles of the cell body (Chittajallu et al., 2004). 
During the differentiation process, OPCs give rise to preoligodendrocytes that extend 
multipolar short processes, loose the mitogenic response to PDGF and have less migratory 
capacity (Gao et al., 1998; Pringle et al., 1993). Pre-oligodendrocytes start to express the 
sulfatide O4 and the receptor GPR17, which persist until the immature oligodendroglial stage. 
GPR17 has been proposed as a crucial “checkpoint” in the maturation process, indeed, it has 
been shown that either its silencing in early OPC or its over-expression in pre-oligodendrocytes 
affects OPC ability to generate mature oligodendrocytes (Fumagalli et al., 2015).  
Upon loss of A2B5 and NG2 markers, pre-oligodendrocytes begin to express microtubule-
associated protein 1B (MAP1B), galactocerebroside C (GalC), CNPase enzyme and become 
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immature oligodendrocytes, post-mitotic cells with long ramified branches, that are committed 
to the oligodendroglial lineage (Pfeiffer et al., 1993; Crociara et al., 2013). 
In the final stages of oligodendroglial development, mature oligodendrocytes synthetized 
myelin proteins, such as myelin basic protein (MBP), proteolipid protein 1 (PLP1) and myelin-
associated glycoprotein (MAG). These cells, in response to pro-myelinating stimulus released 
by neurons or astrocytes, start to enwrap axons with multiple layers of compact myelin, and 
express high levels of the myelin oligodendrocyte glycoprotein (MOG) (Baumann et al., 2001). 
 
Figure 1.6 Oligodendrocyte differentiation stages and their markers (Barateiro et al 2014). 
1.2.2 Extrinsic regulation of oligodendrocyte development and myelination 
It is widely known that many different factors cooperate in the regulation of 
oligodendrocyte development and maturation, including growth factors, neuregulins, 
hormones and neurotransmitters (Figure 1.7).  
The most important mitogen for OPCs is PDGF-A (platelet-derived growth factor A), signaling 
through the receptor PDGFRa expressed by OPC until they start the maturation program 
_______________________________________________________________________________________________INTRODUCTION 
25 
 
(Pringle et al., 1992). It has been also shown that PDGF alone can induce the commitment of 
neural multipotent stem cells to the oligodendroglial lineage, through the expression of the 
transcription factor Olig2 (Hu et al., 2008). PDGF can also be released by neurons and astrocytes 
and mediate pro-survival signals to oligodendrocytes through association with integrin αvβ3 
and the subsequent activation of PI3K/PKC signaling pathways (Baron et al., 2002). Interestingly, 
axonal signals can also stimulate OPC proliferation and survival via interactions with integrin 
receptors. In this respect, neuregulin-1 (NRG1) a member of the NRG superfamily of epidermal 
growth factor-like ligands that are either axonally-bound or secreted, has been shown to bind 
the oligodendrocyte ErbB tyrosine kinase receptors and promote OPC survival though the PI3K/ 
Akt pathway (Mitew et al., 2013). 
Other important OPC mitogens are FGF2 and IGF1. FGF2 promotes PDGF expression and 
extends the time in which OPCs and pre-oligodendrocytes are responsive to PDGF. Due to its 
ability to inhibit OPC differentiation, FGF2, together with PDGF can revert cells from the pre-
oligodendrocyte stage to OPC (Baumann et al., 2001). In addition to its potential involvement 
in OPC specification, IGF1 also helps to promote OPC proliferation and survival by activating 
the PI3K/Akt pathway through IGF1R (Romanelli et al., 2009). It has been shown that IGF1 over-
expression leads to hyper-myelination, whereas, its deletion decreases the number of mature 
oligodendrocytes and myelin production, suggesting that it may play a role also in 
oligodendrocyte maturation (Beck et al., 1995; Ye et al., 2002). Moreover, FGF2 and IGF1 can 
work synergistically, by activating the ERK1/2 pathway, to promote OPC proliferation (Frederick 
et al., 2007). 
Several studies showed that, in addition to mitogen withdrawal, OPCs can also be stimulated 
to differentiate by triiodothyronine hormone 3 (T3) as part of an intrinsic cell division timer 
(Durand and Raff, 2000). Although T3 and mitogen withdrawal may work through different 
signaling pathways, such as p53 or p27/kip1-mediated signaling, respectively, the two 
mechanisms likely co-operate in vivo, regulating a crucial step in myelin development (Durand 
et al., 1997, 1998; Tokumoto et al., 2001). T3 promotes the morphological and functional 
maturation of post-mitotic oligodendrocytes binding its intracellular receptors (TRα1, β1, β2), 
that work as ligand-dependent transcriptional factors (Sarliève et al., 2004). OPC express α1 and 
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β2 isoforms, whereas, mature oligodendrocytes express α1 e β1. T3 signaling can be modulated 
by different factors, such as receptor isoforms, co-receptors, presence of co-activators or co-
repressors and ligands availability. T3 responsive elements (TRE) were identified in the promoter 
regions of MBP and PLP genes, suggesting that T3 directly regulates their expression. (Farsetti 
et al., 1991; Bogazzi et al., 1994). 
In specific conditions, OPC should maintain an immature phenotype, in order that myelin is 
produced in the right place and moment. Thus, oligodendrocyte differentiation onset is also 
tightly regulated by several extracellular inhibitory factors. Among them, Notch1 receptor, 
interacting with its axonal ligands Jagged1 and Delta1, prevents OPC maturation and controls 
when axons should be myelinated (Bozzali & Wrabetz, 2004). Surprisingly, in the presence of 
the axonally expressed F3/contactin, Notch-1 signaling has been reported to promote OPC 
differentiation (Hu et al., 2003).  
 
 
Figure 1.7 Intrinsic (transcription factors and miRNAs) and extrinsic (extracellular ligands and receptors) 
mechanisms regulating oligodendrocyte maturation (Emery et al., 2010). In red, factors inhibiting, 
whereas, in green, factors promoting the expression of myelin genes. 
Another inhibitory mechanism involves the leucine-rich repeat and immunoglobulin domain-
containing-1 (LINGO1), a transmembrane protein expressed on both oligodendrocytes and 
axons. It has been shown that LINGO1-mediated inhibition of oligodendrocyte maturation 
works by decreasing the activity of Fyn kinase, and, in turn, increasing RhoA signaling (Mi et al., 
2005). Indeed, Fyn kinase is involved in the regulation of process outgrowth and morphological 
differentiation of oligodendrocytes. Fyn signals through p190RhoGAP that, by inactivation of 
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RhoA, a member of the Rho family of small GTPases, controls the cytoskeletal structure by 
mediating actin polymerization. Indeed, it has been demonstrated that the constitutive 
expression of active RhoA prevents oligodendrocyte process extension (Wolf et al., 2001). 
As previously mentioned, once oligodendroglial cells become mature oligodendrocytes, they 
must receive the right signals to myelinate axons. The extracellular signals regulating the 
myelination process can be divided in 2 groups:  those that modulate oligodendrocyte process 
extension and axonal contact, and factors that dictate subsequent myelin thickening. 
Most axonal signals identified are inhibitory and prevent the initial myelination or that over-
myelination occurs. Canonical examples include the axonal PSA-NCAM, which is 
developmentally downregulated simultaneously to the myelination onset (Fewou et al., 2007) 
and the already mentioned Notch1 and Lingo1 signaling pathways. However, there are also 
pro-myelinating axonal signals, for example, axonal lamininα2 promotes the initial process 
extension binding to β1 integrin receptors on oligodendrocytes (Hu et al., 2009). This results in 
an activating dephosphorylation of the tyrosine kinase Fyn at the inhibitory Tyr531 site and 
subsequent initiation of actin polymerization and microtubule assembly (Bauer et al., 2009). 
In accordance, genetic ablation of Fyn in mice reduced the number of myelinating axons and 
produced thinner myelin sheats (Goto et al., 2008). Laminin-α2 and β1 integrin mediated 
signaling is also required for determining the correct myelin thickness and axon selection. Other 
modulators of myelin thickness include axonal NRG1 and neuronal BDNF. It has recently been 
shown that BDNF pro-myelinating effects are likely mediated by ERK1/2 and that BDNF receptor 
deletion in oligodendrocytes reduces myelin thickness during development (Xiao et al., 2012) 
1.2.3 Intrinsic regulation of oligodendrocyte development and myelination 
In the CNS, oligodendrocyte development is tightly regulated by intrinsic time-
dependent mechanisms, which modulate cell proliferation and maturation via signalling 
cascades, culminating in the activation of several transcription factors and epigenetic 
modulators, final effectors that can directly influence gene expression (Figure 1.8). 
During embryonic phase, OPC formation is driven by the interaction of the morphogen Sonic 
hedgehog (Shh) with its receptor Patched in neuroepithelial cells, by inducing the expression 
of the transcriptional factors Pax6 (Paired box 6), Nkx6.1, Nkx6.2 e GLIF, necessary for the initial 
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ventrally-derived wave of OPCs (Liu et al., 2003). These factors regulate the expression of the 
bHLH transcription factor Olig2, the best-defined transcription factor in oligodendrocyte 
specification (Lu et al., 2000).  
Several studies demonstrated the fundamental role of Olig2 in oligodendrocyte specification, 
for example it has been shown that Olig2 knock-out mice fail to produce OPCs within most 
regions of the CNS and that ectopic expression of Olig2 in nestin-positive progenitor cells leads 
to an increase number of OPCs (Maire et al., 2010). Nevertheless, Olig2 is not essential for the 
formation of OPCs in some CNS regions, likely because its loss can be compensated by the very 
close bHLH transcription factor Olig1 (Lu et al., 2002).  A stage-specific conditional-KO approach 
suggested that Olig2 plays a role also in OPC differentiation, indeed, its ablation in post-mitotic 
OPCs decreases the number of mature oligodendrocytes. In contrast, its ablation in mature cells 
does not affect myelination (Mei et al., 2013), suggesting a role during OPC maturation rather 
than in control of myelination.  
 
Figure 1.8 Intrinsic regulation of oligodendrocyte differentiation involves the action of stage-specific 
transcription factors and epigenetic modulators (Mitew et al., 2013). 
In the last decades, several transcription factors were identified to be active in maintaining OPCs 
in their undifferentiated stage (mostly Id2, Id4, Sox6, Hes5), leading to hypothesize a de-
repression model of OPC differentiation in which the progressive shutdown of inhibitory signals 
allows the expression of pro-differentiation factors and the induction of OPC maturation (Emery 
et al., 2010). For example, Id2 and Id4 (induced by BMP signaling) inhibit OPC differentiation by 
sequestration of Olig1 and Olig2, thereby preventing their function. Hes5, a bHLH transcription 
factor, induced by Notch signaling, can recruit HDAC-containing repressive complexes and 
inhibit the expression of positive regulators of myelin gene expression, such as Sox10 (Liu et al., 
2006). 
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Olig2 expression precedes other important markers of the oligodendroglial lineage, such as 
Olig1, Nkx2.2, YY1, Sox10, TCF7L2 and MYRF (Wegner et al., 2008), that have a primary role in 
the induction of OPC differentiation and myelination. 
Although Olig1 is expressed from the time of oligodendrocyte specification, some studies 
suggest that it may be also important for the myelination onset, indeed, it has been shown that 
Olig1 KO mice fail to produce fully myelinating oligodendrocytes (Xin et al., 2005). Moreover, 
Olig1, by cooperating with Sox10, can induce the transcription of the MBP gene (Li et al., 2007). 
When oligodendrocytes become matures, a change in the phosphorylation state of Olig1 
causes a change in its localization, moving from the nucleus to the cytoplasm, where it is 
necessary to promote full membrane extension (Niu et al., 2012). One of the inhibitory factors 
down-regulated after Olig1 translocation to the cytoplasm is Nkx2.2. Although Nkx2.2 is 
necessary for post-mitotic OPC formation, it has to be down-regulated concurrent to 
myelination onset, since it can repress MBP transcription (Wei et al., 2005). 
As mentioned before, Sox10 is required for the expression of MBP and the generation of 
myelinating oligodendrocytes. Recent studies showed that Sox10 can also act as co-factor of 
other transcription factors essential for OPC differentiation and myelination, such as TCF7L2 
(Zhao et al., 2016). 
TCF7L2 is transiently expressed in oligodendrocytes and it can have either pro- or anti-
differentiation effects, depending its association partners. In OPCs TCF7L2 form a complex with 
β-catenin (produced in response to Wnt signaling activation) to block OPC differentiation 
(Fancy et al., 2009). Otherwise, follow OPC differentiation onset, TCF7l2 binds Kaiso and form 
complexes with HDAC to repress Wnt-β-catenin signaling and promote OPC maturation. 
Moreover, it has been shown that, in committed oligodendrocytes, TCF7L2 can also bind Sox10 
and promote their terminal differentiation (Zhao et al., 2016). 
Sox10 can also induce myelination by promoting the expression of the pro-myelinating factor 
MYRF. Unlike other transcription factors, that are expressed also in OPCs, MYRF is specifically 
expressed in committed oligodendrocytes (Emery et al., 2009) and is required for the 
progression of pre-myelinating oligodendrocytes to a mature, myelinating state. Conditional 
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ablation of MYRF in mature oligodendrocytes results indeed in a complete loss of myelin genes 
and demyelination, even in adult mice (Koenning et al., 2012). 
Another important regulatory mechanism that controls oligodendrocyte development is carried 
out by HDAC, enzymes that can modify the chromatin acetylation state or physically interact 
with transcription factors to repress gene expression (Figure 1.9). It has been shown that, unlike 
other neural lineages, oligodendrocyte differentiation of progenitor cells is initiated by a global 
histone deacetylation program (Marin-Husstege et al., 2002). During the early phases of 
oligodendrocyte development, HDACs repress the choice of alternative lineages and contribute 
to oligodendrocyte identity by blocking critical transcription factors, in particular Sox2 (Lyssiotis 
et al., 2007; Shen and Casaccia-Bonnefil, 2008). Indeed, it has been demonstrated that the 
pharmacological inhibition of HDACs during the differentiation of neural stem cells causes a 
significant reduction in oligodendrocytes in favor of astrocytes and neurons (He et al., 2007; Liu 
et al., 2007; Siebzehnrubl et al., 2007). Moreover, HDAC inhibition in rodent models delays 
oligodendrocytes differentiation and myelination (Shen et al., 2005). 
The central role of HDACs in oligodendrocyte development was also remarked by an in vivo 
study that showed how the conditional ablation of HDAC1/HDAC2 in Olig1-expressing 
oligodendrocytes resulted in sever hypo-myelination and post-natal death of mice (Ye et al., 
2009). 
Another important aspect is the crosstalk between transcription factors, such as REST and YY1, 
and HDACs, which usually act in combination to repress factors that normally block OPC 
maturation. REST is a transcription factor involved in OPC specification and in the formation of 
chromatin remodeling complexes. It has been shown that REST can recruit the co-repressor 
Sin3a and HDAC1/2 to block the expression of neuronal genes and promote oligodendroglial 
specification (Dewald et al., 2011). Another example is the crosstalk between HDACs and the 
multifunctional protein YY1, a transcriptional factor that can act either as activator or repressor. 
The mechanism involves the recruitment of HDAC1 by YY1 at Id2 and Tcf4 promoter and the 
inhibition of their expression, allowing OPC differentiation. Accordingly, YY1 KO mice show high 
expression levels of the inhibitors Id2 and Tcf4, and defective myelination (He et al., 2007). 
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Sirt2, a cytosolic enzyme highly expressed in oligodendrocytes, that belongs to class III HDACs, 
can instead explicate its deacetylasic activity on alfa-tubulin, probably modulating 
morphological differentiation of oligodendrocytes (Tang and Chua, 2008). 
Lastly, it has been shown that class IV HDACs, such as HDAC11, play a role in myelination. 
HDAC11 is indeed highly expressed during oligodendrocyte maturation and its silencing causes 
a strong decrease in the expression of myelin genes and OPC maturation blockade (Liu et al., 
2009). 
 
Figure 1.9 Epigenetic mechanisms modulating the transition from OPC (left side) to myelin-forming cells 
(right side). In OPCs myelin gene inhibitors recruit HDACs on myelin gene promoters, preventing their 
expression. Then, the progressive decline of inhibitors expression allows the acetylation of activator and 
myelin gene promoters, inducing their expression (Liu and Casaccia 2010).  
1.2.4 Role of miRNAs in the regulation of oligodendrocyte differentiation. 
Several recent studies have addressed the important role of miRNAs in the regulation 
of oligodendrocyte development. First evidences were obtained by Dicer-null experiments, 
which have shown how mice lacking Dicer1 gene die prenatally (Bernstein et al., 2003). 
Gene expression profile studies on oligodendrocytes allowed to identify miRNAs that belong 
to the miR-17~92 cluster, previously categorized as onco-miRs (Ota et al., 2004; Hayashita et 
al., 2005). It has been shown that conditional ablation of miR-17~92 cluster in CNP-expressing 
OPC decreases, whereas, their over-expression increases the number of oligodendrocytes 
(Budde et al., 2010). Subsequent works revealed that this miRNA cluster control OPC 
proliferation by targeting PTEN, which inactivation causes an increase in the proliferation rate 
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through Akt signaling (Harrington et al., 2010). However, as shown by Dicer conditional ablation 
experiments, miRNAs are required for both cell cycle exit and terminal differentiation of 
oligodendrocytes. Indeed, conditional ablation of Dicer in OPCs leads to an initial increase in 
the proliferation, followed by maturation fail, suggesting the existence of miRNA that normally 
inhibit proliferation and promote terminal maturation (Dugas et al., 2010; Zhao et al., 2010a). 
Microarray analysis of mature oligodendrocytes vs. OPCs allowed to identify miRNA that are 
specifically expressed at high levels by mature cells (Figure 1.10), such as miR-219, miR-338 and 
miR-138 (Lau et al., 2008; Dugas et al., 2010). Later, it has been shown that miR-219 is a potent 
activator of oligodendrocytes maturation. Moreover, its exogenous administration rescues 
myelination defects in Dicer-null mice. The mechanism involves the repression of factors that 
normally block OPC maturation, such as Pdgfr-α, Zfp238, Hes5, Sox6 and Foxj3. It has been 
shown that miR-219 is expressed at high levels also in adult mice. Interestingly, conditional 
ablation of Dicer1 in mature oligodendrocytes leads to hypo-myelination, suggesting that 
specific miRNAs, such as miR-219, control myelin formation and maintenance. It has been 
proposed that miR-219 expression in mature cells is necessary to repress its direct target Elovl7 
(Shin., 2009), an enzyme involved in the formation of very-long chain fatty acid (VLCFA), 
essential components of the myelin sheaths. VLCFA over-production was related to different 
de-myelinating disorders (Dubois-Dalcq et al., 1999), thus, miR-219 may be necessary to repress 
Elovl7 activity once axonal myelination is completed.  
Another miRNA highly expressed during oligodendrocytes maturation is miR-338 (Lau et al., 
2008). It has been shown that, similarly to miR-219, miR-338 inhibition increases, whereas its 
over-expression promotes, the differentiation of OPC into mature oligodendrocytes, directly 
repressing Hes5 and Sox6 (Zhao et al., 2010a). It is worth to note, that the expression levels of 
crucial miRNA in oligodendrocytes, such as miR-219 and miR-338, are dependent upon Olig1 
for their expression, suggesting the relevance of miRNA/transcription factors crosstalk in 
oligodendrocyte maturation (Zhao et al., 2010a).  
In addition to miR-219 and miR-338, also miR-138 is more expressed in mature 
oligodendrocytes compared to OPC (Dugas et al., 2010), although it is not as potent as the 
other in the promotion of OPC maturation, performed by Sox4 inhibition. Moreover, it has been 
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shown that sustained expression of miR-138 leads to a reduction in MOG protein, suggesting 
that it can have a transient role in OPC maturation and a Janus role in the terminal phases 
(Galloway et al., 2016). 
miR-23a was initially discovered as a regulator of laminin B1, an inhibitor of myelin genes 
expression (Lin and Fu, 2009). Indeed, miR-23a over-expression in OPC increases CNPase and 
MBP levels. Nevertheless, further studies showed that miR-23a over-expression in CNPase-
expressing oligodendrocytes results in hind-limb paralysis, loss of extensor tone and kyphosis, 
due to hyper-myelination (Lin et al., 2013). The mechanism of action underlies these phenotypic 
changes involves the repression of PTEN, that normally control myelination by limiting Akt and 
IGF1 signaling (Harrington et al., 2010; De Paula et al., 2014). 
 
Figure 1.10 MiRNAs implicated in oligodendrocyte maturation and their target mRNAs (Galloway et al., 
2016) 
MiR-9 play an important role in the regulation of oligodendrocytes maturation by repressing 
PMP22, a peripheral myelin protein. miR-9 is enriched in OPCs of the CNS, but absent in the 
peripheral nervous system (PNS), suggesting that it can have a role in the silencing of peripheral 
genes in the CNS, that are not necessary (Lau et al., 2008; Dugas and Notterpek, 2011). 
Another miRNA recently found up-regulated during oligodendrocyte maturation is miR-297c-
5p, which represses its direct target Cyclin T2, a regulator of cell cycle progression and a 
negative regulator of OPC differentiation (Kuypers et al., 2016). 
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1.3   Multiple sclerosis 
Multiple sclerosis (MS) is a multifactorial chronic immune-mediated de-myelinating 
disorder of the CNS in which immune system attacks myelin, a substance produced by 
oligodendrocytes that normally surrounds and protects axons, leading to abnormal impulses 
transmission. The etiology of MS is still unclear, however, it includes a genetic predisposition 
combined with environmental influences.  
It is estimated that 2.5 million people worldwide are affected by MS, with a prevalence range 
of 100 cases per 100000 people. MS typically affects women more than men. Presentation of 
MS symptoms usually begin between 20 and 50 years of age, less than 1% can occur in 
childhood and approximately 2-10% after 50 years of age (Ghasemi et al., 2017). Patients 
commonly suffer from visual changes, muscle weakness, ataxia leading to falls, paroxysms such 
as tonic spasms and seizures, cognitive impairments, and fatigue. 
MS patients can be divided into 3 subtypes based on the clinical pattern (Figure 1.11). Relapsing 
remitting MS (RR-MS) is the most common subtype (85% of MS patients) and is characterized 
by unpredictable acute attacks (relapses) followed by full or partial recovery (remissions), 
without disease progression between relapses. 
Figure 1.11 Disease progression of different subtypes of MS. 
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Primary progressive MS (10-15 % of MS patients) is a type of MS (PP-MS) with no acute relapses 
or remissions, characterized by accumulation of disability from the onset of symptoms. These 
patients never return to their baseline. Sixty-five percent of RR-MS patients developed into 
secondary progressive MS (SP-MS) with progressive worsening of neurological disability. In SP-
MS, patients can present minor relapses and remissions but they never return to their baseline. 
1.3.1 MS etiology and epidemiology 
Up to date, the reasons for MS incidence have not been found, however, a combination of 
external and environmental factors and genetic predisposition were proposed to be involved 
(Figure 1.12). Since initial exposure to numerous viruses, bacteria and other microbes occurs 
during childhood, and since viruses are well-recognized as causes of demyelination and 
inflammation, infectious agents such as Epstein Barr virus (EBV), human herpes virus type 6, and 
mycoplasma pneumonia were proposed as agents associated to MS onset (Ghasemi et al., 
2017).  
 
Figure 1.12 Factors potentially responsible for MS development. 
In accordance, it is well-documented that in human many viruses were related to demyelination 
Encephalomyelitis and that viral infection also induced demyelination in animal models (Gilden 
et al., 2005). Others environmental factors, such as smoking, vitamin deficiency and exposure 
to UV radiation, can change the risk to develop MS. Smoking leads to the production of nitric 
oxide (NO) and carbon monoxide (CO), substances that can induce mitochondrial damage and 
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lipid peroxidation and, in turn, to oligodendrocyte apoptosis, axonal degeneration and 
demyelination (Mitrovic et al., 1995). 
Growing evidence support that also vitamin D and sunlight exposure can play an important role 
in MS onset. MS prevalence is indeed higher in North America and Europe, due to the decrease 
of sunlight exposure, that, in turn, determines a lower amount of naturally-produced vitamin D. 
On the contrary, people who live closer to equator have a lower risk to develop MS (Figure 
1.13). Accordingly, MS rate in Europe compared to North Europe moves from 100 to 200 MS 
cases per 100000 people (Milo et al., 2010).  
The risk of developing MS could be also associated to genetic components. Studies have shown 
that having a first-degree parent with MS does significantly increase the individual risk. It has 
been estimated that the risk for such those individuals and for dizygotic twins is 2-5% (Willer 
et al., 2003). The risk of MS in family members of a patient depends on the amount of genetic 
information they share. Thus, the risk rate in homozygotic twins (that have 100% genetic 
similarity) is 25%, whereas for second degree relatives is 1-2% (Ebers et al., 1995). Moreover, it 
has been shown that in the HLA region of chromosome 6 exists a group of genes associated to 
an increased risk of developing MS (Baranzini et al., 2011). 
Figure 1.13 Distribution map of MS in the world. 
1.3.2 MS pathophysiology  
The hallmark of demyelinating disease is the formation of sclerotic plaques, that represent the 
final stage of a process involving inflammation, demyelination and remyelination, 
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oligodendrocyte depletion, astrogliosis, neuronal and axon degeneration. However, the order 
and relation of these separate components remain fully to be resolved (Compston et al., 2008). 
The lymphocytic presence within plaques and bordering areas suggests that inflammatory 
destruction in MS is driven by antigen-specific targeting of myelin and other CNS components. 
In particular, adaptive immune responses by T lymphocytes are thought to mediate injury to 
myelin and nerves within the CNS during MS. T cells from MS patients can indeed recognize a 
variety of myelin protein targets, including MBP, PLP, MOG and MOBP, among others.  
Pathogen-associated molecules simultaneously bind to toll-like receptors on APCs (dendritic 
cells, microglia and B cells), that respond by producing specific cytokines, such as IL-12, IL-23 
and IL-4, that induce CD4+ T cell differentiation into Th1, Th2, or Th17 phenotypes (Ghasemi et 
al., 2017). The cytokines produced by Th1 cells are proinflammatory cytokines such as interferon 
gamma, whereas Th2 cells secrete anti-inflammatory cytokines such as IL-4 and IL-13. Th17 is 
a newly recognized CD4+ T cell subset that produces IL-17, IL-21, IL-22 and IL-26. Like Th1 cells, 
Th17 cells promote inflammation in MS (Loma et al., 2011). Interestingly, IL-17 receptors are 
present in acute and chronic MS plaques. Moreover, studies in IL-17 deficient mice show 
reduction of clinical severity (Komiyama et al., 2006). In vitro mobilization studies suggest that 
Th17 cells cross the blood brain barrier (BBB) more efficiently than other T cells, and that are 
capable of eliciting damage to the BBB (Kebir et al., 2007), allowing a greater influx of other 
inflammatory cells.  
Regulatory T cells (T reg) are another CD4+ T cell type involved in the pathogenesis of MS. The 
role of T-reg cells is to regulate effector Th1, Th2 and Th17 cells. The number of T reg cells is 
the same between MS patients and controls, however patients with MS have reduced T reg 
function (Haas et al., 2005).  
Besides the involvement of CD4+ T cells in MS pathogenesis, studies have shown that CD8+ T 
cells are present in MS lesions and may have regulatory function in the progression of disease. 
CD8+ T cells transect axons, promote vascular permeability and activate oligodendrocyte 
death (Kasper et al., 2010). 
In addition to T cells, also B cells and their released antibodies are involved in the pathogenesis 
of MS. In situ deposition of MOG-specific antibodies has been detected in MS lesions, along 
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with MOG- and MBP-specific Ig complexed with myelin within macrophages (Genain et al., 
1999). Modulation of T cell function may be an equally important function of B cells in the 
immune dysregulation in MS patients. B cells may promote neuro-inflammation in MS via direct 
and indirect effects on T cells, such as the secretion of pro-inflammatory cytokines. 
Another key element that contributes to the immune-mediated damage during MS is the 
process by which immune cells are able to gain access to the CNS compartment, generally 
considered restricted. The BBB normally serves to actively restrict cellular and macromolecular 
movement between CNS tissue and the blood and appropriate function of the BBB depends 
from several anatomic and cellular features, such as tight junctions between endothelial cells, 
specific expression of transporters, and vasculature (Daneman et a., 2009).  
 
Figure 1.14 Principal mechanisms contributing to MS pathogenesis (Hemmer et al., 2002). 
In MS, a sequence of critical events allows to auto-reactive lymphocytes to enter in the CNS 
compartment. Initially, leukocytes take contact with endothelium of the BBB, a process 
facilitated by up-regulation of adhesion molecules, such as ICAM1 and VCAM, by the 
vasculature (Piccio et al., 2002). It has been proposed that changes in the vascular endothelium 
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could be mediated from the action of circulating pro-inflammatory mediators, including tumor 
necrosis factor (TNF) and lipopolysaccharide (LPS). Subsequently, migration of cells through 
and between endothelial cells takes place (Holman et al., 2011). Extravasation of immune cells 
in perivascular cuffs within the CNS parenchyma can also occur and lead to a breach in the BBB, 
an essential component in the process of inflammatory destruction of the white matter in MS.  
In MS, leukocyte influx to the CNS is also influenced by the presence of specific chemokines. 
For example, SDF1 is typically localized to the basolateral microvasculature of the CNS and 
functions to retain leukocytes within the perivascular space. Interestingly, redistribution of SDF1 
to the luminal microvasculature was observed in autopsy specimens from MS patients, which 
would induce dissemination of lymphocytes into the CNS parenchyma (Mc Candless et al., 
2008). 
As mentioned before, MS is the most common de-myelinating disease. In the early phase of 
the disease, myelin repair mechanisms are activated in response to the formation of de-
myelinating sclerotic plaques, to produce new myelin. This re-myelination process is carried out 
by OPC, which migrate toward lesions, proliferate and differentiate to oligodendrocytes 
(Franklin, 2002). Nevertheless, after repeated cycles of damage, the re-myelination efficiency 
decreases and oligodendrocytes fail to restore myelin and axonal function. As a consequence, 
axons remain unprotected and degenerate. The reasons for re-myelination failure are not well 
understood, however, patient age, the hostile environment in lesions (myelin debris and 
inflammation) and disease progression itself may negatively influence OPC ability to re-
myelinate (Keough et al., 2013). 
1.3.3 MS Diagnosis and Prognosis  
The diagnosis of MS is based on medical history, neurological examination by imaging 
techniques such as magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) and blood 
sample analysis, and evoked potentials (Røsjø et al., 2014; Figure 1.15). The first neurological 
event that lasts at least 24 hours is termed a “clinically isolated syndrome” (CIS), that is named 
“monofocal”, when a single lesion leads to a single neurological symptom or “multifocal”, when 
more than one lesion causes multiple symptoms (Sturm et al., 2014).  
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The presence of elevated immunoglobulins or oligoclonal bands in the CFS of a patient who 
presents a CIS is consistent with a diagnosis of MS (Polman et al., 2010). 
MRI shows focal or confluent abnormalities in white matter in more than 95% of patients, 
however, their presence alone does not allow the diagnosis of multiple sclerosis, since lesions 
can also appear in people without clinical signs of disease and many individuals older than 50 
years can present non-specific white matter lesions (Compston et al., 2008).  
Given the nature of MS, MRI findings will change over the course of time. For this reason, 
specific criteria that take in account these changes were defined to simplify the diagnosis, 
maintaining sensitivity and specificity (Montalban et al., 2010). 
Figure 1.15. Diagnostic tests used to make initial diagnosis 
According to McDonald criteria, a patient with CIS should also presents specific MRI changes 
to support a MS diagnosis and must include the documentation of lesions disseminated in 
space (DIS) and in time (DIT). DIS requires one or more T2 lesions1 in two or more MS locations 
of the CNS, typically periventricular, juxctacortical, infratentorial, and spinal cord. DIT can be 
established by the presence of a new lesion compared with a previous scan or the simultaneous 
presence of an asymptomatic enhanced lesion plus a T2 non-enhancing lesion on the same 
scan (Polman et al., 2010). 
                                                          
1 hyperintense lesions, or "bright spots", in T2-weighted MRI scans, often referred to as plaques. 
_______________________________________________________________________________________________INTRODUCTION 
41 
 
When CIS are also accompanied by white matter abnormalities, detected by MRI at clinically 
unaffected sites, the chance of a second attack of demyelination (fulfilling the diagnostic criteria 
for RR-MS) increases from 50% at 2 years to 82% at 20 years. As mentioned before, 65% of RR-
MS patients develop in SP-MS, whereas in 20% of patients the illness is progressive from the 
onset. In both situations, the progression typically starts around 40 years and patients often 
manifest a spinal disease. Children with MS are usually women, they reach the secondary 
progressive in more time with respect to adults, but do it at a younger age (Renoux et al., 2007). 
A minority of MS patients present a first attack after 50 years of age and were defined late-
onset MS (LOMS) (Polliack et al., 2001). Since LOMS patients often have atypical presentations, 
misdiagnosis and delayed diagnosis are more common compared to young-onset MS (YOMS) 
patients (Martinelli et al., 2004). 
In RR-MS patients, the risk of a relapse is doubled after viral exposure especially for upper 
respiratory and gastrointestinal infections (Andersen et al., 1993). Conversely, persistent 
parasitic infection seems to protect from disease activity, likely by promotion of T-regulatory-
cell activity (Correale et al., 2007). 
The median time to death is around 30 years from disease onset, representing a reduction in 
life expectancy of 5–10 years (Bronnum-Hansen et al., 2004).  
1.3.4 Biomarkers for MS 
The intrinsic heterogeneity of MS causes that the detection and the prediction of disease 
progression is very difficult, also for the lack of sensitivity in current clinical assessments. 
Treatment decisions are based more on risk rate and trial and error than on objective 
assessments that predict who will respond to any given disease-modifying therapy (DMT, for 
details on DMTs see section 1.3.6). In this respect, the identification of specific biomarkers that 
reflect the disease activity, would allow an individualized clinical management of MS patients 
and to predict treatment response (Harris et al., 2016). Conventional biomarkers are molecular 
markers detectable in body fluids that can sensitively and specifically reflect either a normal or 
pathological process. In MS, the CSF is the most direct source of biomarkers, whereas blood 
can indirectly reflect alteration in CNS mechanisms (Kuhle et al., 2016). 
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Biomarkers could have a high relevance in CIS patients, in order to predict their conversion to 
clinically defined MS. For example, biomarkers correlated to oligodendrocytes loss or axonal 
damage would help to choose the right treatment to prevent or delay the disease progression. 
Since CSF collection is a routine analysis in CIS patients, several biomarker discovery studies 
were performed (Figure 1.16) and many are still ongoing, however the current challenge is to 
understand the reliability of these predictive biomarker and their value in the identification of 
subtype of patients with a poor prognosis. In this respect, Chitinase 3-like-1 (CH3L1) has been 
proposed as a predictive biomarker for the conversion of CIS in clinically defined MS. It has 
been shown that elevated CH3L1 in the CSF correlate with higher probability, and a shorter 
time, to convert from CIS to MS, in addition to a more rapid development of long term disability 
(Hinsinger et al., 2015; Canto et al., 2015). Other markers used to predict the conversion of CIS 
in MS are IgG and IgM oligoclonal bands (OCB) in the CSF (Petzold et al., 2013). Moreover, IgM 
OCBs are also predictive of a more aggressive disease progress, correlate with brain atrophy 
and to CXCL13 levels, chemokine that controls B cell migration (Ferraro et al., 2015). Some 
biomarkers can also be used to monitor the therapeutic effect of DMTs. For example, interferon-
β (IFN-β) and Natalizumab efficacy usually decreases following the formation of neutralizing 
antibodies, thus, serum antibodies are commonly assessed as biomarker of treatment response 
(Harris et al., 2009). Another biomarker used to monitor IFN-β response is myxovirus resistance 
protein (MxA), a gene rapidly induced in peripheral blood mononuclear cells (PBMCs) by IFN-
β. It has been shown that Natalizumab also reduced levels of CH3L1 (Stoop et al., 2013).  
Biomarkers can be also useful to prevent the onset of specific pathological conditions resulting 
from the use of some DMTs. For example, Natalizumab, an immunosuppressive drug that 
reduces relapses in RR-MS patients, has been associated to multifocal leukoencephalopathy 
(PML), a potentially dangerous infection caused by CNS reactivation of the John Cunningham 
virus (JCV). The risk of develop PML in patients under treatment with Natalizumab is reduced 
by monitoring the serum levels of JCV antibody (Lee et al., 2013). It has been shown that the 
levels of some biomarkers in CSF, such as Fetuin-A, osteopontin, and CXCL-13, can correlate 
with disease activity. These factors are present at higher levels in the CSF of CIS, RRMS, SPMS, 
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and PPMS patients compared to symptomatic controls and they decrease in response to 
treatments (Kuhle et al., 2016). 
In the last years, light (NF-L) and heavy (NF-H) neurofilaments are emerging as new biomarkers 
of MS in the monitoring of axonal damage and neurodegeneration, based on their release in 
the extracellular space following axonal injury. It has been shown that levels of NF are high in 
the CSF of MS patient, during relapses. NF-L levels correlate more with the inflammatory 
components of the disease, whereas, NF-H reflect more the progression disability and ongoing 
neurodegeneration (Teunissen et al., 2012).  
A recent study has shown the prognostic value of NF-H, demonstrating that elevated levels of 
NF-H in the CSF of RR-MS patients is predictive of atrophy measured 15 years later (Petzold et 
al., 2016). NF-L levels in the CSF can also correlate with other biomarkers. For example, it has 
been shown that CFS NF-L inversely correlate to serum levels of vitamin D, suggesting that the 
last can also protect from axonal injury (Sandberg et al., 2016).  
 
Figure 1.16. Biomarkers associated with different clinical phases in MS. (Teunissen et al., 2015) 
Currently, several studies are investigating whether NF blood levels sufficiently correlate with 
disease activity, in order to allow less-invasive analysis.  
_______________________________________________________________________________________________INTRODUCTION 
44 
 
Several studies have explored the use of circulating miRNA as biomarker of MS, revealing 
miRNAs that are differentially expressed in MS vs controls, associated to the conversion of CIS 
in MS or that change in response to DMTs. In these studies, miRNA expression was evaluated 
in the CFS, whole blood, plasma, PBMCs, or MS lesions (Table 1.2). 
Junker and colleagues analyzed the expression of 365 miRNAs in 16 active and 5 inactive white 
matter MS brain lesions compared to 9 control white matter specimens. They identified some 
miRNAs expressed by astrocytes, such as miR-155, miR-326 and miR-24a, that are specifically 
up-regulated in MS active lesions, proposing that they can have a role in the regulation of 
macrophages activity (Junker et al., 2010). 
Another study analyzed the expression profile of miRNAs in the CSF of 53 MS patients 
compared to 39 patients with other neurological diseases (OND). Subsequent validation 
experiments by qPCR on the selected candidates revealed that miR-922, miR-181c, and miR-
633 are differentially expressed in patients with MS compared with OND and that miR-181c 
and miR-633 differentiated RRMS from SPMS with 82% specificity and 69% sensitivity (Haghikia 
et al., 2012). Given its greater accessibility and less invasive procedures, several studies in the 
last years evaluated miRNA expression profile in blood samples, such as PBMC, plasma or 
serum, to identify possible biomarkers for MS. For example, miR-20a-5p was reported to be 
down-regulated, whereas miR-22-5p was up-regulated, in the blood samples of MS patients 
compared to healthy controls (HC) (Cox et al., 2010; Siegel et al., 2012). Interestingly, it has also 
been shown that miR-20a-5p is involved in the regulation of T cell activity. In another study 
miRNA expression profile was performed using plasma samples from 10 RRMS, 9 SPMS, and 9 
HC. This study revealed that specific miRNAs can distinguish between MS patients and HC and 
between different MS subtypes. The expression of selected miRNAs was then assessed in a 
larger cohort of MS patients (100) compared to amyotrophic lateral sclerosis (ALS) patients and 
HC. miR-92a resulted useful to distinguish RRMS from SPMS and HCs, and showed association 
with EDSS (Expanded Disability Status Scale) and disease duration (Gandhi et al., 2013).  Let-7a, 
instead, differentiated SPMS from RRMS and HC. Interestingly, these 2 miRNAs are also useful 
to distinguish RR-MS from ALS and they don’t change between SP-MS and ALS, suggesting 
they can have common pathological features.   
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A recent study identified other 2 differentially expressed miRNAs, miR-233 and miR-15b, useful 
to discriminate between RR-MS and PP-MS (Fenoglio et al., 2013).  
 
Table 1.2 List of miRNAs potentially useful as biomarker of MS with the relative source and proposed 
targets. Upper numbers refer to the original reference (Harris et al., 2016 doi.org/10.2147/DNND.S98936). 
It has been demonstrated that the efficacy of some DMTs can be partially related to change in 
the expression level of specific miRNAs that regulate key aspects of MS pathogenesis; thus, 
circulating miRNAs can also be used as treatment response biomarker in MS. For example, it 
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has been shown that Natalizumab treatment caused down-regulation of miR-326b and up-
regulation of miR-20b, which in turn can regulate Th17 immune response and BBB breakdown 
(Ingwersen et al., 2015). 
Another independent study reported that 20 miRNAs take part in the mechanism of action of 
IFN-B and that some of them, such as members of the mir-29 family, are associated with 
apoptosis or have direct relationship with IFN-responsive genes (Hecker et al., 2013). 
In another treatment response study, the expression of 1059 miRNAs was tested in B cells 
isolated from 10 untreated and 10 Natalizumab treated MS patients using microarrays analysis. 
This study showed that 10 miRNAs were differentially expressed in B cells of Natalizumab-
treated patients compared to untreated patients. They also found that the expression of the 
miR-106b-25 and miR-17-92 clusters was dysregulated both in untreated and Natalizumab-
treated MS patients compared to HC, suggesting a role for these miRNAs in MS pathogenesis 
(Sievers et al., 2012). 
1.3.5 Models to study de-myelination and re-myelination 
In order to better understand de-myelination and re-myelination dynamics, several 
experimental models of MS have been developed in the last decades, however, not a single 
model can mimic all the pathophysiological processes that occur in the human disease. For this 
reason, different in vitro, ex vivo and in vivo models are commonly used in combination to 
achieve a complete picture of a mechanism. 
OPCs are the most common in vitro model, widely used to understand myelin development 
and to assess the effects of new agents, in relation to their migration, survival, proliferation and 
differentiation, however, they cannot be used for myelination studies (Osorio-Querejeta et al., 
2017). Given the high difficult to obtain human OPCs, most of the studies make use of OPCs 
obtained from brain cortex of young and adult rodents. Nevertheless, in the last years, human 
iPSCs are emerging as a useful source of human OPCs and can also represent a potential 
therapeutic approach, since they can be obtained by MS patients themselves (Ogawa et al., 
2011). In vitro models based on OPCs are simple and low cost, and can represent an initial point 
to test a compound or to manipulate a specific pathway, to improve their re-myelinating 
capabilities.  Other in vitro models make use of co-cultures, that involve the presence of axons 
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(either natural, e.g. dorsal root ganglion, or artificial, e.g. nanofibers) and myelinating cells (i.e. 
OPCs). Co-cultures can be used to assess the myelination capabilities of the cells under study 
or to investigate the effects of drugs on these cells. Analysis on co-cultures include 
quantification of myelin and g-ratio2 analysis (Osorio-Querejeta et al., 2017). 
Among ex-vivo models, organotypic cultures represent the most common used 3D cultures and 
can be considered an intermediate step between in vitro and in vivo studies. Organotypic 
cultures consist of approximately 300 um slices that mimic the structure and the cell types of 
the origin organ. They can be generated by different CNS structures, such as brain, spinal cord 
and cerebellum (Kipp et al., 2012). 
Usually, for de-myelination/re-myelination studies, organotypic cultures are treated with the 
lysophosphatidylcholine (LPC), a detergent that destroys myelin. Following LPC removal, OPCs 
activate and proliferate in response to de-myelination, and differentiate to mature 
oligodendrocytes, that start the re-myelination process. This model is widely used to test the 
regenerative capacity of endogenous cells and how pharmacological or biotechnological 
interventions can modulate the re-myelination process. Despite they cannot replace in vivo 
models, organotypic cultures can represent a useful tool for screening treatments before in vivo 
testing (Zhang et al., 2011). 
In vivo models for MS have been developed to study pathological processes related to 
demyelination and re-myelination and can be classified in 4 categories: autoimmune, toxic, viral 
and genetic. Animal models can be monitored during disease by magnetic resonance imaging 
and several data can be collected with post mortem analysis (e.g. myelin quality, g-ration, gene 
expression analysis). 
Experimental autoimmune encephalomyelitis (EAE) is the best characterized autoimmune 
model of MS and exhibits several histopathological features of the human disease. In this 
model, animals are immunized against a myelin peptide to induce an T-cell mediated 
autoimmune response against myelin. Depending on the peptide, animal host and viral strain 
different models can be generated, which resemble human SP-MS or RR-MS. Like human MS, 
EAE presents features such as myelin destruction, development of lesions into the CNS, and 
                                                          
2 ratio of the inner to the outer diameter of the myelin sheath of a myelinated axon. 
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presence of immunoglobulins in the cerebrospinal fluid and CNS, however de-myelination and 
re-myelination processes are less extensive (Kipp et al., 2012). Chronic EAE is the most used for 
de-myelination studies and this can be achieved by immunizing C57BL7/6 mice or Dark Agouti 
rats against myelin oligodendrocyte glycoprotein (MOG 35–55) peptide, emulsified in Freund's 
adjuvant that is supplemented with Mycobacterium tuberculosis extract. Chronic EAE is the gold 
standard for pre-clinical proof of concept studies to test new drugs (Constantinescu et al., 2011). 
Nevertheless, it has proven poorly predictive of treatment efficacy in human MS, in particular 
regarding the use of inflammatory cytokines. During EAE development, disease progression can 
be monitored by clinical scores. The main limitations of the model are the high complexity and 
the low reproducibility, which can make interpretation of results very complicated. Moreover, 
EAE cannot provide new insight on progressive-MS and it is not the more suitable model to 
study remyelination, since lesions occur stochastically in time and location (Ransohoff et al., 
2012). 
In toxic models of MS oligodendrocytes are depleted following the injection or administration 
of specific toxic agents. The most widely used toxins are lysophosphatidylcholine (LPC) and 
cuprizone. LPC can damage myelin altering specifically the membrane composition of 
oligodendrocytes. In this model, the demyelinating lesions, characterized by astrogliosis and 
microgliosis, are obtained by stereotaxic injection of LPS in the white matter of mice. The 
damage induces OPC proliferation and migration towards lesions, where they start to 
differentiate in oligodendrocytes and begin the regenerative process (Osorio-Querejeta et al., 
2017). 
Cuprizone is a copper chelating agent that induced selective death of oligodendrocytes and, as 
a consequence, demyelination. The exact mechanism is still unknown, however, it has been 
proposed that cuprizone causes errors in the mitochondrial respiratory chain (Ransohoff et al., 
2012). In this model, cuprizone (0.2% in chow) is usually fed to mice for 4-6 weeks and after 3 
weeks of administration an extensive death of oligodendrocytes in the corpus callosum and 
hippocampus can be observed. Depending on the length of treatment (6 or 12 weeks), 
cuprizone can induce acute or chronic de-myelination. Demyelination and re-myelination 
simultaneously occur as the damage evolves, in a similar way to the human disease. After 
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cuprizone withdrawal, robust re-myelination occurs, but in the chronic models it is slower and 
limited (Kipp et al., 2009). 
In contrast to EAE, T cells do not play a role in the generation of de-myelinating lesions in toxic 
models. These models are simpler and highly reproducible, and can be useful to investigate 
demyelination and re-myelination processes. They can also be used to evaluate the effects of 
drugs or cell therapy (in the absence of high levels of inflammation) on re-myelination, a crucial 
point for neuroprotection in MS, thus representing the most significant tools for translational 
research (Ransohoff et al., 2012).  
Genetic models of MS (also known as myelin mutants) are animals with specific mutations that 
lead to a global failure in myelin production, thus characterized by extensive demyelination. 
These models are widely used for transplantation studies, to test the myelinating capabilities of 
exogenous cells (Duncan et al., 2011). The most commonly used myelin mutant in transplant 
experiments is the shi mouse, which has a mutation in the myelin basic protein (MBP) gene, but 
it is not a model of human disease. Shi mice are characterized by absence of myelin and they 
die at approximately 120 days (Duncan et al., 2011).  
Development of viral models of MS was based on the hypothesis that some virus may cause 
demyelinating disorders such as MS. Given that viral infections are one of the potential causes 
of MS onset in human, these models allow to investigate the potential effects of remyelinating 
and immunomodulatory agents in cells infected by neurotrophic virus (Osorio-Querejeta et al., 
2017).  
1.3.6 Drugs available in clinics and new therapeutic perspectives in MS 
Currently there is not a definitive cure for MS, however, treatments available can efficiently 
decrease symptoms and prevent the progression, reducing the number of relapses. There are 
3 general approach to MS treatment: (1) corticosteroids (CS) for acute relapses; (2) DMT to 
reduce relapses and prevent disability; (3) minimize the impact of quality life treating MS-
associated symptoms (Sturm et al., 2014). 
Corticosteroids are potent anti-inflammatory and immune-suppressive agents, which are 
commonly used to treat MS related exacerbations (relapses). Benefits of corticosteroids are 
related to their capability to restore the integrity of the BBB and to reduce the migration of 
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inflammatory cells into the CNS, and subsequently increase the speed of recovery after MS 
relapses (Ontaneda et al., 2009). 
In 2016, 11 disease-modifying agents have been approved by the U.S. Food and Drug 
Administration (FDA) for the relapsing-remitting MS subtype: daclizumab, glatiramer acetate, 
interferon beta-1a, interferon beta-1b, dimethyl fumarate, fingolimod, teriflunomide, 
alemtuzumab, mitoxantrone, natalizumab and ocrelizumab. Currently, interferons and 
glatiramer acetate are the best treatments, indeed both are effective in reduce MS relapses by 
30% and are safe for longer therapy (Johnson et al., 2009). Although the exact mechanism of 
action of beta-interferons is unknown, it may be related to suppression of T-helper cell 
response. Glatiramer acetate, instead, mimics myelin basic protein and induces Th2 cells 
activation. 
Natalizumab can reduce relapses more efficiently, but it has several side effects and, for this 
reason, it is used in non-responsive or MS advance patients (Tsang et al., 2011), similarly to 
Mitoxantrone. In the last years, several oral drugs, such as teriflunomide, fingolimod, and 
dimethyl fumarate, have shown efficacy in RR-MS patients. Phase 3 clinical trials (FREEDOMS, 
TEMSO and DEFINE) showed reduction of the absolute relapse rate (ARR), reduction in the 
number of new T2 lesions and in gadolinium enhancing-lesions, but their uses are limited due 
to lack of long term data efficacy and safety (Killestein et al., 2011). 
There are also new treatments making use of monoclonal antibodies such as ocrelizumab, 
rituximab and ofatumumab. These category of drugs targets the antigen CD20, a 
transmembrane protein expressed by B cells with possible role in activation and differentiation. 
Different phase 2 and 3 clinical trials showed that anti-CD20 mAbs can significantly reduce new 
brain MRI lesions and relapses in RRMS and be effective in a subset of PPMS patients (Barun at 
al., 2011). 
Despite all the mentioned immunosuppressive agents have shown a beneficial effect in the 
treatment of RR-MS, they are almost useless in the progressive forms. Only recently, a phase 3 
clinical trial completed in December 2016 showed that PP-MS patients treated with 
Ocrelizumab had a slower disease progression compared to placebo treated patients 
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(Montalban et al., 2017). Thus, Ocrelizumab is the only agent approved by FDA for the treatment 
of PP-MS. 
Currently, all the treatments available for MS are immunomodulating and anti-inflammatory 
agents, which can delay the progression and decrease the pathological symptoms, however, 
they do not halt the ongoing de-myelination and the subsequent neurodegeneration. 
Therefore, other strategies such as use of stem cell-based therapy or re-myelinating agents are 
under investigation as potential novel paradigms for the treatment of MS. 
Several studies on animal models of MS showed efficacy of MSC (mesenchymal stem cells), NSC 
(neural stem cells), OPC or ADSC (adipose-derived stem cells) transplantation. It has been 
proposed that the beneficial effect of MSC transplantation could be due to their 
immunomodulatory properties and paracrine effects (Mohyeddin Bonab et al., 2013). 
Functional recovery observed after NSC transplantation is instead associated to re-myelination 
improvements (Pluchino et al., 2003). Other studies have shown that also ADSC transplantation 
can decreased pathological signs and de-myelination in rodent model of MS (Ghasemi et al., 
2016; Shalaby et al., 2016). ADPC can differentiate in other cell lineages and secrete 
neurotrophic factor, suggesting that their transplantation could promote tissue regeneration 
(Ghasemi et al., 2017). 
As previously discussed, re-myelination is essential to restore axonal conduction and plays a 
primary role in clinical recovery and remissions. Extensive re-myelination can occur during early 
disease and in the remitting phases, however, it declines dramatically in the progressive phase, 
contributing to neurodegeneration. Thus, foster endogenous re-myelination could have a 
strong impact in these progressive forms. Moreover, they can also be used in a combination 
therapy with the already available DMTs. 
High-throughput screening of previously FDA-approved drugs allowed to identify several 
classes of pro-myelinating drugs. For example, anticholinergics, such as benzotropine and 
clemastine, have shown pro-myelinating effects, likely via antagonism of M1/M3 muscarinic 
acetylcholine receptors directly expressed by oligodendrocytes (De Angelis et al., 2012). 
Another small molecule screening identified miconazole, an antifungal agent, and clobetasol, a 
corticosteroid used to treat eczema. It has been shown that these molecules can exert they re-
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myelinating properties by influencing eIF2, thyroid hormone and cholesterol signaling directly 
on oligodendrocytes (Najm et al., 2015). The safety profile of these agents was already 
established, thus, a phase 2 clinical trial could be done in the next future.  
Olesoxime, a mitochondrial pore modulator originally developed to treat ALS, accelerates 
oligodendrocyte differentiation and myelination either in vitro and in vivo without affecting 
oligodendrocyte survival or proliferation (Bordet et al., 2007). A phase 1b study to evaluate the 
safety of this agent in MS patients is currently ongoing. 
Another possible strategy to foster re-myelination is to modify the local environment, in order 
to make it more permissive for endogenous OPC. In this respect, one promising target is 
LINGO1, an already discussed negative regulator of myelination (see 1.2.2). A phase 2 clinical 
trial with IgG1 anti-LINGO1 was already done and produced good results in the treatment of 
optic neuritis, leading to faster nerve impulse conduction, indication of myelin repair (Harlow 
et al., 2015). Another promising target is represented by semaphorin 4D (SEMA4D), normally 
expressed by mature oligodendrocytes. It has been demonstrated that SEMA4D is up-regulated 
after injury and increases oligodendrocytes apoptosis. Moreover, its over-expression in DRG 
co-cultures inhibits myelination, whereas, its silencing in oligodendrocytes after spinal cord 
injury promotes functional recovery (Zhang et al., 2014). A recent study has shown that 
antibodies against SEMA4D improved BBB integrity, OPC maturation and myelination (Smith et 
al., 2015) in the EAE model of MS. A phase 1 trial for the evaluation of humanized anti-SEMA4D 
safety was recently completed. 
As discussed above, several strategies to foster endogenous re-myelination are under 
investigation, however, up to date, advancements in the detection of myelin specific changes 
are necessary to fully evaluating the efficacy of re-myelinating agents in clinical trials. However, 
several studies suggest that the next frontier in MS therapy will be supplement 
immunomodulators to pro-remyelinating agents, in order to block disease progression and 
recover neurological functions.  
1.3.7 MiRNA as therapeutic targets in MS  
As previously discussed, several studies have shown the important role of miRNAs in the 
regulation of development, homeostasis and maturation of either OPCs and immune cells. Thus, 
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it is not surprising that some miRNAs were directly linked to MS pathogenesis and recently 
proposed as new potential therapeutic targets for MS (Junker et al., 2011; Dugas et al., 2010; 
Thamilarasan et al., 2012; Wang et al., 2017). Depending on the target, modulators of miRNA 
expression can act as pro-remyelinating agents or as disease-modifying therapy. 
Recent studies have demonstrated that miR-155 silencing could repress the activity of Th1 and 
Th17 cells and subsequently reduce disability in EAE mice. Accordingly, administration of anti-
miR-155 in mice significantly decreased EAE development. miR-155 was also found up-
regulated in plasma and active lesions in MS patients, thus, representing a good therapeutic 
target in MS (Ma et al., 2014). Similarly, miR-326 is up-regulated in MS active lesions and its 
expression highly correlates with MS patient’s disability. Moreover, miR-326 in vivo silencing 
reduced, whereas its over-expression increased, the number of Th17 cell and EAE severity (Du 
et al., 2009).  
Another promising therapeutic target is miR-23b, that can repress IL-17 production and NFkB 
activation in EAE mice (Zhu et al., 2012). Down-regulation of miR-125a-5p in MS patients was 
recently associated to BBB dysregulation and thus it could be used to rescue BBB integrity in 
MS treatment (Reijerkerk et al., 2013). It has been reported that miR-27b, miR-128 and miR-340 
can induce the shift from a Th2 to a Th1 cytokines production and that they are up-regulated 
in CD4+ T cells isolated from MS patients. Interestingly, in vitro silencing of these miRNAs 
restores Th2 responses in T cells from MS patients, suggesting that they could represent new 
targets for MS treatment (Guerau de Arellano et al., 2011). 
As previously discussed, re-myelination failure in MS is frequently due to an impairment in the 
maturation of oligodendrocytes, thus, the study of miRNAs regulating OPC differentiation could 
help to identify novel targets to foster endogenous re-myelination in MS patients. In this 
respect, miR-219 and miR-338, miRNAs highly expressed by mature oligodendrocytes, were 
found to be strongly down-regulated in MS brain lesions, suggesting that restoring of their 
physiological levels could promote re-myelination in MS (Junker et al., 2009) 
The property of miRNAs to simultaneously regulate the expression of multiple genes is the main 
feature that attracted the attention of researchers and clinicians to consider miRNAs as a new 
promising category of drugs, but is also the major critical point. Indeed, the main issue about 
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the systemic use of miRNAs in therapy would be to overcome potential side effects arising from 
the ability of miRNAs to regulate multiple genes in different cell types, leading to unwanted 
silencing effects (De Faria et al., 2012). Moreover, miRNAs share common problems with other 
drugs, such as stability, cytotoxicity and delivery to target cells. In this respect, chemical 
modifications have proven efficacy to increase miRNA stability to endo- and eso-nuclease (Van 
Rooij et al., 2014), whereas, packaging of miRNAs into lipid vesicles conjugated to appropriate 
receptors could help to delivery miRNAs to the correct cell type and reduce off-target effects 
(Baumann and Winkler, 2014). Interestingly, it has been shown that exogenous miRNAs can also 
successfully delivered by HDL particles purified from the blood (Vickers et al., 2011).  
Given the high heterogeneity of cell types involved in MS pathogenesis and the pleiotropic 
effect of miRNAs, understand how a candidate miRNA can affect the phenotype of individual 
cell types in the CNS is a critical point for the identification of new miRNA-based drugs for the 
treatment of MS. 
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The discovery of microRNAs (miRNAs) unveiled a new level in the regulation of gene expression 
and opened new directions in all fields of science. Up to date, thousands of miRNAs were 
identified and, given that a single miRNA can modulate hundreds of targets, they represent a 
powerful system in the fine tuning of gene expression. It has been shown that specific miRNAs 
are expressed at high levels in the central nervous system (CNS) and that they participate in the 
regulation of crucial processes related to neural cell development (Petri et al., 2014). As a 
consequence, dysregulation in miRNA levels can contribute to the onset and to the 
pathogenesis of several neurological diseases, such as multiple sclerosis (MS). MS is a chronic 
autoimmune demyelinating disease in which immune system attacks and disrupts myelin, a 
fatty substance produced by oligodendroglial cells that surrounds and protects axons, leading 
to an incorrect transmission of nerve impulses and severe disability (Wu et al., 2011). In MS, 
remyelination can occur as a spontaneous regenerative process following demyelination, but 
this process is often incomplete, likely due to the fail in the maturation of oligodendrocyte 
precursors, the cells responsible for myelin production (Kuhlmann et al., 2008). 
Interestingly, several studies on animal models of MS and human specimens suggested that 
miRNAs can contribute to MS pathogenesis and may play an important role in the re-
myelination failure (Junker et al., 2011; Dugas et al., 2010; Thamilarasan et al., 2012; Wang et al., 
2017). 
Unfortunately, the number of miRNAs fully characterized in MS context is still poor, therefore, 
the main aim of this study was to evaluate the potential role of miR-125a-3p, a brain enriched 
miRNA, in OPC maturation and myelination. 
In particular, we aimed to: 
i. Assess the relevance of miR-125a-3p to oligodendrocyte maturation; 
ii. Characterize its expression in the CNS and oligodendroglial cells; 
iii. Evaluate the effects of miR-125a-3p manipulation in oligodendroglial cells; 
iv. Analyze its expression in animal models of de/re-myelination; 
v. Evaluate the effects of miR-125a-3p manipulation in demyelinating conditions; 
vi. Analyze its expression in the cerebrospinal fluid of human MS patients; 
vii. Identify the mechanisms altered by miR-125a-3p in oligodendroglial cells; 
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The identification of new miRNAs regulating oligodendrocyte maturation may help to find new 
therapeutic targets to foster endogenous re-myelination in diseases characterized by myelin 
defects, such as MS. Moreover, miRNA levels in body fluids can reflect disease activity and their 
restoration could be a novel means to evaluate the efficacy of available treatments, thus 
representing useful biomarkers of disease progression and in personalized pharmacology. 
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3.1 In silico and statistical analysis 
3.1.1 In silico analysis. MyMir (http://www.itb.cnr.it/micro), a system based on integration, 
filtering and re-ranking of outputs produced by different miRNA databases (i.e. TargetScan, 
RNAHybrid, miRanda, PITA) was used for the prediction of miRNA target transcripts. STRING 
database was used to obtain the list of the Gene Ontology biological processes (GO BPs) 
significantly enriched (p value < 0.05) for miR-125a-3p targets. For the analysis, the false 
discovery rate (FDR) adjusted p-value was used, to reduce the chance of false-positive results. 
The fold enrichment in miR-125a-3p was calculated using the following formula as previously 
described: 
(1) Fold enrichment = 
m n
M N


  
m = genes target in a BP; n = all genes target in the list; M = all genes in a BP; N = all genes in 
the genome. A fold enrichment greater than 1 (expected value) indicates that the category is 
overrepresented in the input list.  
QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) was used to build the network model for the synergic regulation 
of MBP and to perform the upstream regulator analysis on differentially expressed genes after 
miR-125a-3p over-expression. Z score > 2 indicates that a transcriptional regulator is likely 
activated, whereas Z score < 2 indicates that it is likely inhibited in the experimental condition. 
The software MetacoreTM was used to perform an ontology-based clusterization on 
differentially expressed genes after miR-125a-3p over-expression in OPCs, to identify common 
processes. 
3.1.2 Statistical analysis. Data are presented as mean ± standard error (SEM) of replicates. 
GraphPad Prism 6.0 was used for statistical analysis. For all comparisons between two groups 
with a normal distribution, two-tailed unpaired t-test was performed. For multiple comparison 
testing, one-way analysis of variance (ANOVA) accompanied by Dunnett’s post-hoc test was 
used. For CSF samples, data with a Median Absolute Deviation (MAD) > 3.5 were considered 
outliers and discarded from the analysis. P values <0.05 were considered statistically significant. 
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3.2. Cell cultures and miRNA transfection 
3.2.1 Primary cultures and OPC isolation. Primary mixed glial cultures were obtained from 
postnatal day 2 (P2) Sprague-Dawley rat cerebral cortices. After the removal of meninges, 
cortical tissues were diced with a sterilized razor blade and transferred into a 50 ml sterile 
centrifuge tube (Euroclone) containing ice-cold Hanks balanced salt solution with calcium and 
magnesium (HBSS, Euroclone). Afterwards, HBSS was aspired and tissues were washed with 
HBSS without calcium and magnesium and incubated with 10 ml trypsin-EDTA solution 
containing 1% DNAse I (final concentration 0.01 mg/ml) (Sigma-Aldrich) for 30 minutes in a 
water bath at 37°C for tissue disaggregation. After the incubation, trypsin was inactivated with 
HBSS containing 10% of fetal bovine serum (FBS, Euroclone) and tissues were further triturated 
mechanically with a Pasteur pipet. The cellular suspension was passed through a 100 μm cell 
strainer (BD) in order to eliminate undissociated tissue residues, collected into a 50 ml sterile 
centrifuge tube and centrifuged at 1200 rpm for 10 minutes. The supernatant was discarded 
and the pellet was resuspended in the medium for cortical astrocytes containing: DMEM high 
glucose (Euroclone), 2 mM L-glutamine (Sigma-Aldrich), 1 mM Sodium pyruvate (Sigma-
Aldrich), Penicillin 100 U/ml-Streptomycin 100 μg/ml (Euroclone), 2,5 μg/ml Fungizone 
(Euroclone) and 20% FBS. The cellular suspension was spread over the entire T75 poly-D-lysine 
(final concentration 10 μg/ml, Sigma-Aldrich) -coated flask surface. Then, flasks were put in a 
tissue culture incubator (Steri Cult 200) at 37°C, 5% CO2 and 95% relative humidity. The medium 
was changed every 2-3 days until cell confluence (about 8 days after the plating).  
Flasks were then removed from the incubator, well fixed with the plug-seal cap tightly screwed 
on a horizontal orbital shaker and shaken for 20 minutes at 200 rpm at room temperature to 
remove microglial cells. The medium containing microglial cells was discarded from the flasks 
by aspiration and 12 ml of fresh DMEM containing 10% of FBS were added to each flask. The 
flasks were put again on the shaker for further 3-4 hours to isolate OPCs. The cell suspension 
from each flask was then collected by a pipette, transferred to an untreated Petri-dish and 
incubated for 20 minutes in tissue culture incubator at 37 °C for differential adhesion of 
contaminating microglia and astrocytes. The cell suspension was transferred into a 50 ml tube 
and centrifuged at 1200 rpm for 15 minutes. The supernatant was carefully discarded and the 
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pellet was resuspended and dissociated in a small amount of Neurobasal (Life Technologies) 
containing 2 mM L-Glutamine, 1% of Penicillin 100 U/ml-Streptomycin 100 μg/ml and 2% of 
B27 (Life Technologies). Living cells were counted using the Trypan blue which allows the 
exclusion of death cells. OPCs were plated onto poly-D,L-ornithine-coated (final concentration 
50 µg/ml; Sigma-Aldrich) 13-mm glass coverslips for immunocytochemistry (2-3 x 104 
cells/coverslip) and poly-D,L-ornithine-coated 6-wells plates (105 cells/coverslip) or 6-cm dishes 
(2.5 x 105 cells/coverslip) for qRT-PCR assays. Cells were plated in Neurobasal medium 
supplemented with 2% B27, 2 mM L-glutamine, 10 ng/ml human platelet-derived growth factor 
BB, and 10 ng/ml human basic fibroblast growth factor to promote proliferation. When OPCs 
reached a 60% confluency, cultures were switched to a Neurobasal medium lacking growth 
factors and containing triiodothyronine 15 nM (T3, Sigma-Aldrich) to allow differentiation. In 
selected experiments, T3 was not added to induce a slower maturation.  
The primary cultures used for the experiments were derived from rats. All the procedures were 
performed in accordance with the approved national law, with the implementation of European 
Union Directive nr. 86/609/CEE regarding the Protection of animals used for experimental 
research. The experiments were approved by the Council of the Dipartimento di Scienze 
Farmacologiche e Biomolecolari, Università degli Studi di Milano, Italy, which is legally entitled 
for the use of animals for scientific proposes (D.M. of Italian Ministry of Health, Authorization 
#295/2012-A 12/20/2012, according to the D.lgs 116/92). 
3.2.2 Transfection of primary OPCs with miR-125a-3p mimics and inhibitors. OPCs were 
transfected immediately after switching from proliferating to differentiating medium (in the 
absence or in the presence of T3). MiR-125a-3p mimics or hairpin inhibitors (Dharmacon) were 
transfected at the final concentration of 50 nM. A scrambled miRNA transfection was included 
as negative control. MiRNAs were transfected with Lipofectamine RNAiMAX reagent (Life 
Technologies) following the manufacturer’s protocol.  
3.3 Immunofluorescence and in situ hybridization  
3.3.1 Immunocytochemistry and cell counting. Cells were fixed in a 4% paraformaldehyde 
phosphate-buffered solution containing 4% sucrose. The following primary antibodies were 
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used: rabbit anti-Olig2 (1:100; Millipore), rabbit anti-GPR17 (1:100; Cayman Chemical), rat anti-
MBP (1:200; Merck Millipore), goat anti-MAP1B (1:300; Santa Cruz), mouse anti-O4 (1:100; 
R&D), mouse anti-GFAP (1:100; Cell signalling). Incubation of primary antibodies were 
performed 2.5 hours at room temperature or over-night at 4°C. Cells were then incubated for 
1 h at room temperature with secondary antibodies conjugated to either AlexaFluor 488 or 
AlexaFluor 555 (1:600; Life Technologies). All the antibodies were diluted in a phosphate-
buffered blocking solution (pH 7.4) containing 0.3% Triton X-100, with the exception of O4, 
which did not require detergents. Nuclei were labeled with the UV fluorescent dye Hoechst 
33258 (1:10,000; Life Technologies). Coverslips ere then mounted in a fluorescent mounting 
medium (Dako). Positive cells for the selected markers were counted from 20 random fields for 
each coverslip (0.07 mm2/field). The result was expressed as a percentage over the number of 
nuclei, and then normalized versus controls (transfected with negative miRNA) set to 100%. 
3.3.2 MicroRNA in situ hybridization in combination with immunohistochemistry. After 
anaesthesia, post-natal P7, P14 and adult rats (or mouse) were perfused with 4% 
paraformaldehyde (PFA; Sigma) in phosphate buffered saline (PBS). Brains were explanted and 
post-fixed in 4% PFA for 1 hour. Embryos and P2 rat brains were fixed by immersion in 4% PFA 
for 4 hours. Tissues were washed in PBS, dehydrated overnight in 30% sucrose, and then 
embedded in OCT (Bio-optica). Twelve micrometer sections were cut on a cryostat in RNase-
free conditions, transferred to Superfrost/plus microscope slides (Thermo Scientific), and stored 
at 20°C. Buffers and reagents were prepared using DEPC-treated (Sigma) water and autoclaved. 
Detection of miRNA was performed with miRCURY LNA miRNA detection probes (Exiqon), using 
a previously described protocol63 with minor modifications. Briefly, tissues were further fixed 
in 10% formalin (Sigma) and then subjected to acetylation. Pre-hybridization was carried out 
for 2 hours at room temperature, followed by hybridization with scramble/miR-125a-3p DIG-
LNA probes (20nM; Exiqon) overnight at 55°C. The following day, endogenous peroxidases were 
blocked with 1% H2O2 (Sigma). For probe detection, the sections were incubated with a sheep 
anti-DIG-POD primary antibody (1:600; Roche), diluted in blocking buffer (0.05% Tween-20, 1% 
BSA and 1% sheep serum, all from Sigma) at room temperature for 2 hours, then with 
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biotynilated-tyramide for signal amplification (Perkin Elmer) and finally streptavidin Alexa Fluor 
555 conjugated (1:1000; Life Technologies) for 50 minutes. 
For detecting the epitopes of interest, immunohistochemistry (IHC) was combined with in situ 
hybridization (ISH) by using the following primary antibodies: rabbit anti-Olig2 (1:100; 
Millipore), rabbit anti-Iba1 (1:500; Wako), mouse anti-GFAP (1:100; Cell Signaling), mouse anti-
NeuN (1:100; Millipore), mouse anti-Nestin (1:100; Millipore), rabbit anti-NG2 (1:100; Millipore), 
mouse anti-CC1 (1:50; Calbiochem). Alexa Fluor 488 or 633 (1:600 and 1:300, respectively; Life 
Technologies), were used as secondary antibodies in double or triple staining. Stainings with 
Alexa Fluor 633 were always shown in either white or blue pseudocolor. Nuclei were labelled 
with the UV fluorescent dye Hoechst 33258 (1:20,000; Life Technologies). Finally, slides were 
mounted in a fluorescent mounting medium (Dako). 
3.4 Gene expression analysis 
3.4.1 Total RNA extraction, retrotranscription and gene expression analysis. Total RNA 
was extracted from rodent cells or tissues using Trizol reagent (Life Technologies). Human RNAs 
(total brain, brainstem, frontal cortex, kidney and liver) were bought from Ambion. For qRT-PCR 
of miRNA, 10 ng of total RNA was reverse-transcribed with TaqMan® MicroRNA Reverse 
Transcription Kit and then subjected to Taqman microRNA assay (Life Technologies). Expression 
level of miR-125a-3p was normalized to the U87 snRNA in rat samples and to the U6 snRNA in 
mouse and human samples by the ΔCt method. For gene expression analysis, cDNA synthesis 
was performed starting from 800 ng of total RNA using SuperScript® II Reverse 
TranscriptiScript cDNA synthesis kit (Biorad). The expression of all genes was analyzed with 
Universal SYBR Green Supermix (Biorad) and normalized to GAPDH expression using CFX96 real 
time PCR system (Bio-rad) following the manufacturer’s protocol. 
3.4.2 Isolation of miRNAs from cerebrospinal fluid (CSF) and real-time PCR. Human 
samples of CSF have been obtained from the Institute of Experimental Neurology (INSpe) 
Biobank at the San Raffaele Hospital after thorough evaluation of neuropathology and 
consisted of MS, Alzheimer, and neurologically normal control subjects. The distinction between 
patients who had radiologic or clinical evidence of MS activity was done through the 
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assessment of gadolinium-enhancing lesions on cranial MRI and presence of recent clinical 
relapses (Fox et al., 2014). According to the recently updated McDonald criteria (Polman et al., 
2011), patients have been considered to be in a clinical relapsing phase of the disease if they 
experienced a relapse in the 30 days prior to lumbar puncture. Patients with one or more 
gadolinium-enhancing lesions at baseline MRI (with or without corresponding clinical 
symptoms) were classified the same as in a relapsing (active) phase of the disease. 
The specimens were collected from adult subjects under informed consent in accordance with 
the laws and with the internal guidelines and regulations of the San Raffaele Hospital. The 
protocols were approved by the Ethical commitee of the San Raffaele Hospital. The analysis on 
human specimens were also approved by the Ethical Committee of the University of Milan (prot. 
71/14). CSF samples were collected by diagnostic lumbar puncture or puncture of Ommaya 
reservoirs3 from individual MS patients, centrifuged at 13,000g for 5 minutes and stored at -
80°C. RNA was isolated from 200 µl of CSF using miRNeasy Serum/Plasma Kit (Qiagen, Milan) 
following the manufacturer’s protocol and reverse-transcribed with TaqMan® MicroRNA 
Reverse Transcription Kit (Life Technologies). Expression level of miR-125a-3p was analyzed 
with TaqMan® MicroRNA Assays and normalized to spiked-in cel-miR-39 by the ΔCt method. 
3.4.3 Microarray. RNA quality was assessed with Agilent 2100 Bioanalyzer (Agilent 
Technologies). RNA with RNA integrity number (RIN) > 7 was used for microarray analyses. 
Labeled cRNA was synthesized from 100 ng of total RNA using the Low Input Quick-Amp 
Labeling Kit, one color (Agilent Technologies) in the presence of cyanine 3-CTP. Total RNA was 
hybridized on SurePrint G3 Rat Gene Expression Microarrays (#G4858A-074036, Agilent 
Technologies). This microarray consists of 60-mer DNA probes synthesized in situ, which 
represent 30,584 rat transcripts. Hybridization was performed at 65°C for 17 hours in a rotating 
oven. One-color gene expression analysis was performed according to manufacturer’s 
procedure. Feature Extraction 10.7.3 software (Agilent Technologies) was used to obtain 
microarray raw-data. A fold change of ±1.5 and a FDR-adjusted p-value < 0.05 were considered 
to obtain the list of genes differentially expressed between the two experimental conditions.  
                                                          
3 surgically implanted device that provides direct access to the cerebrospinal fluid. 
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3.4.4 Pathway-focused PCR arrays. The PCR arrays “Wnt signaling targets” (PARN-243ZD) 
and “Extracellular Matrix & Adhesion Molecules” (PARN-013ZD) were used to identify genes 
differentially expressed in OPCs after miR-125a-3p over-expression compared to negative 
control (See Appendix B and C for the list of genes analyzed). For each PCR array, cDNA 
synthesis was performed starting from 500 ng of DNase pre-treated total RNA using RT2 First 
Strand Kit (Qiagen), following manufacturer’s protocol. RT2 Profiler PCR Array (SABiosciences) 
and RT2 SYBRgreen Mastermix (Qiagen) were used to measure gene expression levels. Each 
array includes five housekeeping genes, that enable normalization of data, a genomic DNA 
control, that specifically detects genomic DNA contamination, a reverse transcription control, 
that tests the efficacy of the reverse-transcription reaction and a positive PCR control, that tests 
the efficacy of the polymerase chain reaction itself. Data were analysed by RT2 Profiler PCR Array 
data analysis center v. 3.5 (Qiagen). 
3.4.5 Cloning and luciferase reporter assay. The web tool RNA22 was used to identify 7 
hypothetical binding sites for miR-125a-3p on GPR17 3’UTR. To construct the reporter plasmid 
pmirGLO-UGPR17, a 3’UTR region of 736 bp, containing the 3 more conserved binding sites 
between rat and mouse, was amplified from rat cDNA using the following primer: Fw-
CTTCACAAAGCCCAGGTCAG; Rv-CTGGGGAAGGAAGGGTCAAA. The PCR product was digested 
with SacI and XbaI and was cloned into the pmirGLO Dual-Luciferase miRNA Target Expression 
Vector (Promega). 10 ng of plasmid were transfected alone or together with miR-125a-3p 
mimics (or scramble miRNA, 50 nM) in COS7 cells. Cells were lysed 24 hours after transfection. 
Dual luciferase reporter assay was performed to evaluate the luminescence signal produced in 
the different conditions. 
3.5 Models of de/re-myelination 
3.5.1 Cuprizone-induced demyelinating model. 40 male C57BL/6 wild-type mice were 
housed on-site under normal light/dark cycle conditions. Mice (8-week-old age) were fed with 
0.2% (w/w) oxalic bis-cyclohexylidenehydrazide (cuprizone; Sigma-Aldrich) supplemented diet 
ad libitum for 5 weeks and were then switched to normal diet for further 3 weeks to allow 
spontaneous re-myelination. Real time PCR analysis was performed on the corpus callosum 
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only. Groups of 5 animals were sacrificed at 0, 1, 2, 3, 5, 6, 7 and 8 weeks from the beginning of 
the experiment. Whole brain was explanted and allocated in a brain matrix to produce 5 coronal 
sections of 1 mm interval. Section were fresh frozen in dry ice and lastly processed one by one 
to excide the corpus callosum. Corpus callosum sections were lysed in 500 µl of Trizol reagent 
(Life Technologies). 
3.5.2 Organotypic cerebellar slices. 250 µm-thick parasagittal slices of postnatal day 10 (P10) 
mouse cerebellum were cut using a Tissue Chopper. The slices were placed on Millicell-CM 
culture plate inserts (Millipore) in a pro-survival medium composed by 50% basal medium with 
Earle’s salts, 25% Hanks’ buffered salt solution, 25% horse serum, and 5 mg/ml glucose at 37°C. 
For the induction of demyelination, at 4 days in vitro (DIV) slices were incubated with fresh 
medium including lysolecithin (Lysophosphatidylcholine, LPC, Sigma-Aldrich) overnight (15–17 
hr) at 37°C. After incubation, the LPC-containing medium was replaced with fresh medium. 
Slices from 3 millicells (12 slices) were lysed together 3-days post-demyelination with 500 µl of 
Trizol (Qiagen) for the subsequent RNA extraction. 
3.5.3 Lysolecithin-induced de-myelinating model and lentiviral infection. Focal 
demyelination was obtained in 3-4 month old C57BL/6 mice by a bilateral stereotaxic injection 
of 1ul of a 1% LPC in 0.9% NaCl solution into the subcortical white matter at coordinates: 1 mm 
medio-lateral, 0.1 mm rostral to bregma and at 1.2 from the cortical surface. Lentiviral infection 
(stereotaxic injection of 1ul of 109-concentrated replication-incompetent viral particles) was 
performed in the same sites 9 days later. Animals were sacrificed by intracardial perfusion at 21 
days post lesion. Brains were explanted and post-fixed in 4% PFA for 1 hour. 
Immunohistological procedures were performed according to standard protocols (Boda et al., 
2011). Brain slices were stained to detect the expression of different antigens: GFP (1:700, 
Invitrogen); NG2 (1:200, Millipore). Quantitative evaluations (marker coexpression in GFP-
tagged infected cells) were performed on confocal images by employing the Neurolucida 
(MicroBrightfield, Colchester, VT) or ImageJ (Research Service Branch, National Institutes of 
Health, Bethesda, MD) softwares. Measurements derived from at least 3 sections per animal. At 
least three animals were analyzed for each experimental condition.
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4.1 MiR-125a-3p potentially targets genes involved in oligodendrocyte 
differentiation 
To evaluate the potential relevance of miR-125a-3p in oligodendrocyte differentiation 
and myelination, we first performed an in silico analysis on mouse databases. We used MyMir, 
a software that performs meta-predictions based on integration, filtering and re-ranking of 
outputs produced by different miRNA databases and we obtained a list of 1,673 unbiased 
putative target transcripts of this miRNA. Then, by using STRING, a Gene Ontology (GO) based 
tool, we found that these targets were significantly clustered in 485 GO biological processes 
(GO BPs), suggesting that miR-125a-3p can take part in their regulation. According to previous 
findings showing that miR-125a-3p is a brain-enriched miRNA, we highlighted that many GO 
BPs include nervous system development, neurogenesis, glial cell differentiation, myelination, 
and oligodendrocyte differentiation (Fig. 4.1). For all of them, we calculated and reported the 
fold enrichment in miR-125a-3p targets (see equation (1) in Methods) and we found that the 
BPs related to oligodendrocyte differentiation have a higher enrichment among all the CNS-
related BPs, strongly supporting the hypothesis that miR-125a-3p takes part into 
oligodendroglial cell maturation. 
4.2 Time-regulated expression of MiR-125a-3p in cultured OPCs 
To assess the expression of miR-125a-3p in the CNS, we measured its levels by means 
of real-time PCR in several rodent and human tissues and cells. The analysis showed that indeed, 
miR-125a-3p it is more abundantly present in the CNS of both rat and human. In adult rat, the 
highest expression was found in both total brain and spinal cord, whereas very low levels were 
found in kidney, heart, lung, stomach and liver (Fig. 4.2a). We performed the same analysis on 
human samples, and, among the analysed tissues, miR-125a-3p was found mainly expressed in 
brain tissues, with a significant enrichment in frontal cortex compared to whole brain and also 
in brain stem and corpus striatum (Fig. 4.2b). In line with the rodent data, lower expression 
levels were found in kidney and liver, confirming the brain enrichment of this miRNA. Then, we 
asked whether miR-125a-3p is regulated in rat developing brain. To this aim, we collected RNA 
from total rat brain at different ages starting from embryonic day 14 (E14) to adulthood (6 
months of age).  
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Figure 4.1 Gene Ontology biological processes (GO BPs) related to oligodendrocyte development 
are enriched in miR-125a-3p targets. The genome-wide miRNA target identification tool MyMir was 
used to obtain the list of 1700 miR-125a-3p putative targets. These potential target genes were then 
significantly clustered in 486 GO BPs by means of STRING database. For each category related to nervous 
system development the fold enrichment in miR-125a-3p targets was calculated (see methods). 
Histograms in red show the fold enrichment in miR-125a-3p targets for each selected GO BP (fold 
enrichment compared to expected value = 1; see left axis). Gray diamonds represent p-value (with FDR 
correction) of the prediction for each GO BP (see right axis; log
10
 scale).  
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Levels of miRNA were already high at E14, gradually declined up to postnatal day 0 (P0), 
remained low after birth up to P5, increased immediately before myelination onset and then 
remained mostly stable until adulthood (Fig. 4.2c). 
To evaluate the distribution of this miRNA in the different neural cell types during brain 
development, we took advantage of in situ hybridization (ISH) in combination with 
immunohistochemistry for cell markers, namely Nestin for multipotent neural stem cells, NeuN 
for neurons, GFAP for astrocytes, Olig2 for oligodendrocytes and Iba1 for microglia. In 
embryonic brain, miR-125a-3p was found widespread in the whole parenchyma with a higher 
signal in the ventricular zone (Fig. 4.2d), where it mostly co-localized with Olig2, which, at this 
stage, labels a pool of precursor cells that will give rise to both OPCs and neurons (Takebayashi 
et al., 2000), and to a lower extent with Nestin. In postnatal brain, the expression of miR-125a-
3p is restricted to neurons, both in cortex and striatum, and oligodendrocytes (Fig. 4.2e), 
whereas only a few cells also expressed GFAP and no apparent co-localization was found with 
microglia.  
Then, we focused on oligodendrocytes, and evaluated whether miR-125a-3p is 
preferentially expressed in early OPCs expressing the proteoglycan NG2, or in more mature 
CC1+ oligodendrocytes. To this aim, we performed a triple immunofluorescence staining using 
the same ISH technique described above for miR-125a-3p in parallel with anti-NG2 and anti-
CC1 antibodies in both postnatal (P7) and adult brains, in particular, corpus callosum, where a 
large number of oligodendrocytes could be analysed. In postnatal brain, some cells already 
expressed CC1 and virtually all of them were also decorated with the probe for miR-125a-3p 
(Fig. 4.2e). As expected, the number of CC1+ cells in the adult brain was much higher, but also 
in this case, virtually all cells expressed miR-125a-3p. Both in P7 and adult brains, co-localization 
between miR-125a-3p and NG2 was also found, but only in a subpopulation of cells, with a 
further trend toward a decrease in the adult, suggesting that miR-125a-3p serves a more critical 
function in mature oligodendrocytes. Then, to assess if the expression timing of miR-125a-3p 
indeed changes during oligodendrocyte maturation, we used cultured OPCs to measure its 
expression during their in vitro differentiation.  
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Figure 4.2 Expression of miR-125a-3p in physiological conditions. (a, b) miR-125a-3p relative 
expression was analyzed using Taqman assay in different rat and human tissues and compared to level 
measured in brain. Neural tissues showed higher expression with respect to other tissues. Data were 
expressed as mean ± SEM, n = 3; two-tailed unpaired t test *p < 0.05, **p < 0.01, ***p < 0.001 vs. total 
brain. (c) The levels of miR-125a-3p were analyzed during rat brain development and normalized to the 
levels at P0. Data were expressed as mean ± SEM, n = 4 animals for each time-point; one-way ANOVA 
with Dunnett’s post-test ***p < 0.001 vs. P0. (d) In situ hybridization of miR-125a-3p (red fluorescence) 
in combination with different lineage markers during rat brain development from embryonic day 14 (E14) 
to adulthood. In embryonic brain, the ventricular zone (vz) was chosen. In postnatal brain neurons stained 
with NeuN were shown in cerebral cortex (cx), whereas Olig2
+
 oligodendrocytes were shown in corpus 
callosum (CC). Iba1 and GFAP were shown in triple stainings (white pseudocolor) to identify microglia 
and astrocytes, respectively. (e) In situ hybridization of miR-125a-3p (in red) in double staining with both 
NG2 (early OPC marker; in green), and CC1 (marker of mature oligodendrocytes; in blue). Micrographs 
show representative pictures of corpus callosum of P7 rats (upper panels) and adult rats (lower panels). 
White arrows highlight co-localization of miR with NG2, while yellow arrows refer to co-localization with 
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CC1. (f) Time-course of mir-125a-3p expression in OPCs was analyzed in differentiating conditions and 
normalized to the levels in undifferentiated OPCs (day 0). MiR-125a-3p levels progressively raised, 
reaching a 2.5-fold increase after 6 days in culture. Data were expressed as mean ± SEM, n = 6; one-way 
ANOVA with Dunnett’s post-test; *p < 0.05, **p < 0.01 vs. day 0. 
Interestingly, the levels of miR-125a-3p progressively increased in OPCs kept in cultures under 
differentiating conditions with the triiodothyronine hormone (T3), reaching a 2.5-fold increase 
after 6 days (Fig. 4.2f) compared to the initial proliferating conditions (day 0, in the presence of 
growth factors and in the absence of T3).  
Globally, the in vivo and in vitro data suggest multiple developmental roles for miR-
125a-3p, that, during embryonic life, is expressed at high levels in neural undifferentiated 
precursors likely to prevent their untimely commitment, and that, within cells of the 
oligodendroglial lineage, it could crucially regulate maturation by repressing early transcripts 
important for the maintenance of OPCs at an undifferentiated state.  
4.3 Over-expression of miR-125a-3p delays oligodendrocyte precursor cell 
maturation and re-myelination. 
Since we were interested in myelination, we investigated more in detail the possible role 
of miR-125a-3p during physiological differentiation of OPCs to mature oligodendrocytes, 
performing gain- and loss-of-function experiments. 
When OPCs are cultured in the absence of growth factors and in the presence of the T3 
hormone, they undergo rapid in vitro differentiation, whose phases can be easily monitored by 
staining cells for progressively more mature oligodendrocyte markers (drawing in Fig. 4.3).  
To evaluate the possible role of miR-125a-3p in OPC differentiation, we overexpressed it by 
transfecting cells with a specific miR-125a-3p mimic the same day of growth factors withdrawal 
when the endogenous levels of miR-125a-3p were low. Then, we performed 
immunofluorescence staining for the myelin basic protein (MBP), a typical marker of mature 
oligodendrocytes and counted cells in mimic-transfected cultures and in control conditions 
(cells transfected with scramble double-stranded RNA). Two days after miR-125a-3p mimic 
transfection, the number of MBP+ cells was strongly reduced compared to controls, suggesting 
an effect on terminal maturation (Fig. 4.3a-c). 
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Figure 4.3 Effect of over-expression or inhibition of miR-125a-3p during oligodendroglial 
differentiation. To evaluate the time-dependent effects of either the overexpression or the silencing of 
miR-125a-3p on OPC maturation 4 different markers of progressive differentiation stages were analysed 
by immunocytochemistry, GPR17 and O4 (which label pre-oligodendrocytes), MAP1B (which labels a 
slight more advanced stage) and MBP (which labels terminally differentiated cells). Cells were stained for 
the selected markers 48 h after transfection of miR-125a-3p mimic or inhibitor, in the presence or in the 
absence of the T3 hormone. (a-h) The drawing represents a schematic timeline of the fast differentiation 
protocol in the presence of T3, showing the presented markers. (a, b) Representative micrographs of 
MBP-positive oligodendrocytes after transfection of miR-125a-3p mimic in presence of T3 were shown. 
(c, d, e, f) Histograms show the changes in the number of cells positive for MBP (n=10), GPR17 (n=8), 
O4 (n=2) and MAP1B (n=3) with respect to negative controls. Data were expressed as mean ± SEM, two-
tailed unpaired t test *p < 0.05, ***p < 0.001 vs. negative control.
 
(g, h) Transfection of OPCs with the 
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inhibitor of miR-125a-3p (in presence of T3) led to a significant increase in the number of MBP-positive 
(n=4; p-value=0.0376), but not GPR17-positive (n=7) cells. Data were expressed as mean ± SEM, two-
tailed unpaired t test *p < 0.05 vs. negative control. (i-l) A second differentiation protocol in the absence 
of T3 (slower protocol) was used. Also in this case, the drawing represents a schematic timeline showing 
the presented markers.
 
(i, j) Representative micrographs of GPR17-positive oligodendrocytes after 
transfection of miR-125a-3p mimic in absence of T3 were shown. (k, l) Histograms show a considerable 
decrease in the number of GPR17- (n=7) and MAP1B-positive
 
(n=3) cells after transfection with the mimic 
in the absence of T3 with respect to the negative control. Data were expressed as mean ± SEM, two-tailed 
unpaired t test *p < 0.05 vs. negative control. 
Since MBP is not present in the list of miR-125a-3p putative targets obtained from MyMir, we 
reasoned that miR-125a-3p inhibitory effect is likely exerted on upstream players in the 
pathway culminating with OPC maturation and MBP expression. Thus, we also counted cells 
positive for earlier oligodendroglial players, such as, sequentially, GPR17 (a marker of early 
precursors and intermediate immature oligodendrocytes), O4 (a marker of immature 
oligodendrocytes), and the microtubule associated protein MAP1B (that labels a slightly more 
advanced differentiation stage compared to O4, see drawing in Fig. 4.3). While the number of 
cells positive for GPR17 and O4 were unaltered (Fig. 4.3d, e), the number of MAP1B+ cells was 
reduced by approximately the 50% after mimic miR-125a-3p treatment (Fig. 4.3f), suggesting 
inactivation of transcripts specifically involved in the progression between the O4 and the 
MAP1B stage. To confirm the importance of miR-125a-3p in OPC maturation, in a parallel 
experiment, OPCs maintained under the same culture conditions were transfected with a hairpin 
inhibitor RNA that specifically inactivates miR-125a-3p. A marked increase in the number of 
MBP+ cells was found, yet with no significant effect on the number of GPR17+ cells (Fig. 4.3g, 
h). Globally, these data suggest that miR-125a exerts a silencing effect on transcripts typical of 
OPC differentiation stages that are upstream to MAP1B but downstream to GPR17 and O4. 
Then, we wondered whether mimic overexpression in cultured OPCs maintained under slower 
differentiating conditions could also affect the expression of these earlier transcripts. 
To test this hypothesis, we cultured OPCs in the absence of both growth factors and T3. Under 
these settings, OPCs did undergo spontaneous differentiation in culture, but did not reach 
terminal maturation within the experimental observation times, thus representing a useful 
paradigm for our purpose (see drawing in Fig. 4.3). As expected, under this culturing protocol, 
almost no MBP+ cells were detected; however, upon mimic overexpression, the number of both 
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GPR17+ cells and of MAP1B+ cells were strongly reduced (of -60% and -35%, respectively, Fig. 
4.3i-l) compared to controls.  
These data demonstrate that if differentiation proceeds at a lower speed, miR-125a-3p can also 
act on early targets, whereas, if differentiation is faster, miRNA can only act on later transcripts 
that are closer to terminal maturation. These data also suggest that the post-transcriptional 
regulation of genes involved in oligodendrocyte maturation vary depending on basal or 
stimulated conditions such as those occurring upon CNS damage, when recruitment and 
differentiation of OPCs is rapidly and markedly improved to sustain myelin repair (Reynolds et 
al., 2002). 
To evaluate whether miR-125a-3p over-expression could delay myelination or 
exacerbate a pathological condition, we took advantage of the lysolecithin model, in which the 
detergent lysolecithin (LPC) is used to induce a focal demyelination injury in the white matter.  
In this model OPCs start to activate and proliferate in response to the toxic damage 3 days post 
lesion (dpl), they differentiate from 7 dpl and start to re-myelinate from 10 dpl, completing the 
process at 21 dpl. Stereotaxic injection of 1% lysolecithin was performed in the subcortical white 
matter of adult mice. The over-expression of miR-125a-3p was performed by lentiviral infection 
in the same site at 9 dpl, then animals were sacrificed at 21 dpl (Fig. 4.4a). The lentivirus is not 
selective for any cell types, but its infection can be followed by the GFP reporter protein (Fig. 
4.4b), whose gene is carried by the vector. To evaluate the degree of maturation of infected 
cells we performed a double staining for NG2, marker of oligodendroglial precursor cells, and 
the reporter GFP. The analysis was performed comparing the number of NG2/GFP double-
positive cells on the total amount of infected oligodendroglial cells, between mice receiving the 
lentiviral vector expressing miR-125a-3p and mice infected with lentiviral control. Interestingly, 
we found that miR-125a-3p over-expression increased the number of GFP positive infected 
cells that still express the early marker NG2 at 21 dpl compared to control (Fig. 4.4c), suggesting 
that miR-125a-3p over-expression delayed the maturation of these cells and hindered the re-
myelination process.  
Globally these data showed that high levels of miR-125a-3p can negatively modulate OPC 
maturation either in physiological and pathological context. 
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Figure 4.4 MiR-125a-3p over-expression inhibits re-myelination following lysolecithin (LPC) 
induced de-myelination. (a) Stereotaxic injection of the detergent lysolecithin (1%, 2 µl) was performed 
in the subcortical white matter of C57BL/6 adult mice to produces a focal demyelinating injury. Over-
expression of miR-125a-3p was performed by lentiviral infection in the same site 9 days later, then 
animals were sacrificed at 21 days post-lesion. (b) Infected cells start to express the reporter green 
fluorescent protein (GFP). (c) The histogram shows the proportion of GFP
+
/NG2
+
 and GFP
+
/NG2
-
 
oligodendroglial cells after miR-125a-3p (n=5) over-expression compared to control condition (mice 
infected with lentivirus-CTR, n=3). Over-expression of miR-125a-3p caused an increase in the amount of 
oligodendrocyte precursors expressing NG2 over the total infected oligodendroglial cells (GFP positive 
oligodendrocytes), suggesting that miR-125a-3p over-expression produced an impairment in the 
maturation process.  
4.4 MiR-125a-3p levels are up-regulated in experimental models of toxic de-
myelination 
To better elucidate whether miR-125a-3p could have a pathogenetic role in de-
myelinating diseases, such as MS, we analysed its expression in two different models of toxic 
demyelination induced by either cuprizone or lysolecithin injection.  
For the cuprizone induced demyelination study we used C57BL6 8 weeks old male mice. 
Animals received a 0.2% cuprizone supplemented diet for up to five weeks to induce de-
myelination of the corpus callosum. Then, they were switched to standard diet to allow 
spontaneous re-myelination. 5 animals were sacrificed every week and gene expression analysis 
was performed on the explanted corpus callosum of each animal (Fig. 4.5a).  
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Figure 4.5 miR-125a-3p is up-regulated in the corpus callosum of mice in response to cuprizone-
induced de-myelination. (a) C57BL6 adult mice were fed with a 0.2 % cuprizone supplemented diet up 
to 5 weeks to induce de-myelination of the corpus callosum and then they were switched to normal diet 
up to 3 weeks to allows spontaneous re-myelination. 5 animals were sacrificed for each time-point and 
the corpus callosum was explanted from each animal for the independent evaluation of MBP and miR-
125a-3p expression levels. (b) MBP expression levels strongly decreased after just a week of cuprizone 
administration (W1), remained low until the switch to normal diet (W2-3-5) and then they returned to 
basal levels (W6-7-8), confirming a strong de-myelination of the corpus callosum followed by a successful 
re-myelination. Data were expressed as mean ± SEM; * p≤0.05, ** p<0.01, *** p<0.001 One-way ANOVA 
with Tukey’s multiple comparison test. (c) MiR-125a-3p levels were up-regulated in the corpus callosum 
after 3 weeks of cuprizone administration (W3), suggesting that the detrimental behavior can induce its 
expression. Data were expressed as mean ± SEM; * p≤0.05, ** p<0.01 One-way ANOVA with Tukey’s 
multiple comparison test vs T0. 
As expected, MBP expression levels dramatically decreased after just 1 week of cuprizone 
treatment, confirming the correct de-myelination of the corpus callosum, and, albeit 
progressively rising, remained lower than control until the switch to normal diet. Then, MPB 
levels returned to basal levels, demonstrating the successful re-myelination (Fig. 4.5b). 
Interestingly, we found that miR-125a-3p expression was up-regulated after 3 weeks of 
cuprizone administration and remained high also after the switch to the normal diet (Fig. 4.5c). 
______________________________________________________________________________________________________RESULTS 
78 
 
To univocally correlate miR-125a-3p alteration to demyelinating conditions we took advantage 
of organotypic cerebellar cultures, another well-established model to investigate demyelination 
and re-myelination processes. Cerebellar slices were obtained from p10 mice and then cultured 
with high concentration of growth factors to promote their survival (see Methods).  
Figure 4.6 MiR-125a-3p is up-regulated in organotypic cerebellar cultures following lysolecithin 
induced de-myelination. (a) Cerebellar slices were obtained from p10 mice and cultured in presence of 
growth factors for 4 days. Then they were treated with the detergent lysolecithin to induce local 
demyelination and lysed at 3-days post-lesion to analyze miR-125a-3p expression levels. DIV = days in 
vitro (b) A significant up-regulation of miR-125a-3p levels was found 3 DPL (days post lesion), suggesting 
that this alteration could be a hallmark of white matter demyelination. Data were expressed as 
mean ± SEM; ** p<0.01 Unpaired t test.  
Slices were treated over-night with the detergent lysolecithin to induce local de-myelination 
and they were lysed 3 days post lesion for gene expression analysis (Fig. 4.6a). Interestingly, 
also in this model miR-125a-3p was significantly up-regulated in the de-myelination phase (Fig. 
4.6b), suggesting that its up-regulation could indeed represent a hallmark of white matter de-
myelination. 
4.5 MiR-125a-3p is up-regulated in the cerebrospinal fluid of multiple sclerosis 
patients 
MiRNAs are stable in body fluids and their alterations in plasma and cerebrospinal-fluid 
(CSF) may represent novel biomarkers for the diagnosis and prognosis of human diseases. It 
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has been proposed that circulating miRNAs are originated by passive leakage from broken cells, 
thus reflecting the disease state of injured tissues.  
Since progressive loss of the ability of OPCs to generate mature oligodendrocytes is a well-
known feature of both human MS and other demyelinating diseases, we wondered whether 
miR-125a-3p was also altered in the CSF of MS patients. We thus measured miR-125a-3p levels 
in CSF samples from 30 MS patients (28 patients with the relapsing-remitting and 2 with the 
secondary-progressive form), 11 of which had clinically or neuroradiologically active disease 
(active lesions) at the time of CSF withdrawal. We compared MS patients to a control group 
mainly encompassing non-Alzheimer dementias and normal pressure hydrocephalus patients, 
and to a pure Alzheimer’s patients group (AD) (demographic data of the patients are 
summarized in Table 4.1).  
Diagnostic 
group 
n 
Sex 
F:M 
Age 
y, mean 
miR-125a-3p 
log2 fold increase 
p-value 
vs CTRL 
HC 13 1.6 75.9 0.000 ± 0.141 - 
AD 17 2.4 72.6 0.030 ± 0.125 0.645 
Active-MS 11 1.75 32.1 0.700 ± 0.185 0.003 
Inactive-MS 19 3.75 34.8 0.152 ± 0.178 0.469 
Table 4.1 Demographic data and miR-125a-3p log2 fold increase by diagnostic group. 
 Quantitative real-time PCR analysis revealed a significant upregulation (up to 4-fold) of miR-
125a-3p in the active MS group compared to both HC, AD and inactive MS groups (Fig. 4.7). 
Applying One-way ANOVA to consider multiple comparisons, active MS was still significantly 
different from the control group (p=0.02). Although these findings are not sufficient for 
proposing miR-125a-3p as a biomarker for MS, our results indeed suggest its potential clinical 
relevance in this disease. 
4.6 MiR-125a-3p can modulate OPC maturation acting on multiple targets 
It has been previously shown that the receptor GPR17 play an essential role in the 
regulation of oligodendrocyte maturation and that its early silencing leads to the block of OPC 
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differentiation. Interestingly, GPR17 was predicted as a direct target of miR-125a-3p. Thus, we 
decided to explore the possibility that GPR17 down-regulation observed after miR-125a-3p 
over-expression (Fig. 4.3k) could be the result of a direct interaction between this miRNA and 
the GPR17 transcript.   
Figure 4.7 MiR-125a-3p is upregulated in the cerebrospinal fluid of MS patients in active phase. 
MiR-125a-3p levels were analyzed in the cerebrospinal fluid of AD and MS patients and compared to a 
control group mainly encompassing non-Alzheimer dementias patients. A significant increase in the 
relative expression of miR-125a-3p was found by qRT-PCR in the cerebrospinal fluid of active (relapsing) 
MS patients (n=11) compared to control (C; n= 13; p value = 0.004), Alzheimer (AD; n=17; p value = 
0.004) and inactive (remitting) MS (n=19; § p=0.0545) groups. Data were expressed as mean ± SEM; * 
p≤0.05, ** p<0.01 Unpaired t test.   
First, we used the web tool RNA22 to identify the number and the location of all miR-125a-3p 
hypothetical binding sites and their corresponding heteroduplexes in the GPR17 3’UTR. Thanks 
to this bioinformatic approach we identified 7 hypothetical binding sites in the 4 Kb GPR17 
3’UTR and we selected a short region of 736 bp, containing the 3 more-conserved sites in 
mouse and rat, to be used for a specific reporter assay (Fig. 4.8a). 
This region of 736 bp was cloned into a pmiRGLO construct (which owns constitutive luciferase 
activity) downstream a gene encoding for a luciferase enzyme under the control of a moderate-
strength promoter. To assess the ability of miR-125a-3p to bind GPR17 3’UTR, we co-
transfected this construct together with the miR-125a-3p mimic in COS7 cells, an easy to 
transfect cell line usually used in this type of experiments, and we performed a luciferase 
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reporter assay (Fig. 4.8b), comparing the bioluminescence produced by the luciferase in this 
condition with respect to control (scramble double-stranded RNA and mock transfection). The 
interaction of the miRNA mimic with the predicted target sites downstream the luciferase gene 
should lead to a reduced production of luciferase enzyme and a subsequent decrease in the 
bioluminescence signal. However, in our experiments miR-125a-3p was not able to decrease 
bioluminescence (Fig. 4.8c), suggesting that the effective binding site responsible for GPR17 
down-regulation could be in another region of the 3’UTR or that the effect on GPR17 expression 
may be indirect. 
 
Figure 4.8 Evaluation of GPR17 as a direct target of miR-125a-3p (a) The presence and the location 
of miR-125a-3p binding sites in GPR17 3’UTR was assessed through the miRNA prediction tool RNA22. 
7 hypothetical binding sites were identified. A portion of GPR17 3’UTR of 736 bp length, containing the 
3 more conserved sites between rat and mouse, was cloned into a pmiRGLO construct downstream a 
gene encoding for a firefly luciferase (luc2) under the control of the moderate-strength PGK promoter. 
(b) MiR-125a-3p mimics and the reporter plasmid pmiRGLO-UGPR17 were co-transfected in COS7 cells 
and the ability of miR-125a-3p to interact with the inserted binding sites and affect the luciferase 
expression was assessed evaluating the luminescence signal produced compared to control (scramble 
miRNA or mock transfection) by a dual luciferase reporter assay. (c) The histogram shows that in this 
condition miR-125a-3p was not able to reduce the luminescence signal. 
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Based on the current knowledge, a single miRNA can interact with hundreds of target 
transcripts with “imperfect matches”; this unique feature enables a fine titration of several 
players of the same pathway at the same time. Since, as mentioned, Mbp is not a predicted 
target for miR-125a-3p, we used QIAGEN’s Ingenuity Pathway Analysis tool (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity) to evaluate how alterations of already validated 
targets of the myelination pathway such as SMAD4, Fyn, RhoA, p38 and NRG1 could potentially 
influence MBP expression, thus being responsible for the observed delay in oligodendroglial 
maturation. This analysis showed that not only NRG1 and Fyn, but also RhoA and p38 (that are 
downstream targets of Fyn signaling) can directly or indirectly promote MBP expression, 
suggesting that miR-125a-3p may limit oligodendroglial maturation through inhibition of some 
of these targets, if not all (Fig. 4.9a). To confirm this hypothesis, we performed quantitative real 
time PCR experiments after miR-125a-3p over-expression in OPCs, and found that the expected 
reduction of MBP mRNA was also accompanied by significant downregulation of both Fyn, 
NRG1 and MAP1B (Fig. 4.9b). 
 
Figure 4.9 Model representing the connections between miR-125a-3p and MBP. (a) The model 
shows how miR-125a-3p can influence MBP expression, acting on some predicted (MAP1B) and validated 
targets (SMAD4, p38, RhoA, NRG1 and Fyn). All these direct targets converge in a pathway leading to the 
maturation of oligodendrocytes. (b) To confirm this mechanism qPCR experiments were performed after 
miR-125a-3p over-expression in OPCs, founding that both Fyn (n=3), NRG1 (n=3), MAP1B (n=3) and in 
turn MBP (n=5) mRNA were significantly down-regulated in these conditions. Data were expressed as 
mean ± SEM, two-tailed unpaired t test *p < 0.05 vs. negative control =100. 
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4.7 Transcriptomic analysis on OPC after miR-125a-3p over-expression 
After showing the final effect of miR-125a-3p modulation on OPC differentiation, we 
decided to investigate the pathways influenced by its alteration, which could be responsible of 
the maturation impairment. To this purpose, we performed a transcriptomic analysis on OPCs 
after miR-125a-3p over-expression, applying the “fast” differentiation protocol (see Fig. 4.10a). 
Total RNA was hybridized on SurePrint G3 Rat Gene Expression Microarrays (#G4858A-074036, 
Agilent Technologies), which represent 30,584 rat transcripts.  
 
Figure 4.10 Gene expression profiling of OPCs after miR-125a-3p over-expression. (a) Primary 
cultured OPCs were grown for three days in presence of growth factors, then they were transfected with 
the negative control or miR-125a-3p mimic in presence of hormone T3 to promote cell maturation and 
finally lysed 48 hours after transfection, for the subsequent RNA extraction and microarray analysis. The 
microarray revealed 1060 genes significantly modulated after miR-125a-3p over-expression. (b) Among 
the top 50 up-regulated genes during OPC maturation (Dugas et al., 2006) 25 genes were down-
regulated in OPCs after miR-125a-3p over-expression, confirming the strong impairment in the 
maturation process. 
A fold change of ±1.5 and a FDR-adjusted p-value < 0.05 were considered to obtain the list of 
genes differentially expressed between the two experimental conditions (miR-125a-3p 
transfected OPC vs scramble RNA transfected OPC). Thanks to this analysis we identified 1060 
genes significantly modulated after miR-125a-3p over-expression.  
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To better understand the effect of miR-125a-3p over-expression on OPC maturation, as a first 
analysis, we crossed the list of down-regulated genes in our dataset with the top 50 up-
regulated genes during OPC maturation (Dugas et al., 2006). Interestingly, among the top 50 
up-regulated genes, 25 were down-regulated (Fig. 4.10b), in line with our data demonstrating 
that miR-125a-3p over-expression exerts a strong negative effect on OPC differentiation. 
Then, the list of differentially expressed genes was analysed by two different 
approaches: pathway oriented (IPA) and Gene Ontology-based analysis. The software IPA was 
used to perform an upstream regulator analysis, that allows to identify transcriptional regulators 
that may be responsible for the observed expression changes in the experimental dataset and 
to understand whether they are likely activated or inhibited.   
Master 
regulator 
Molecule type Prediction Z Score p-value 
Number of 
targets 
TCF7L2 transcription factor Inhibited -5.186 5.21E-08 27 
BDNF growth factor Inhibited -2.381 4.23E-06 26 
CXCL8 cytokine   -1.219 8.54E-06 8 
1L1B cytokine   1.349 3.26E-05 30 
IFNG cytokine Activated 2.541 1.26E-04 36 
TGFB1 growth factor   1.451 1.69E-04 55 
LIF cytokine   1.362 3.29E-04 14 
STAT1 transcription factor Activated 2.592 3.95E-04 14 
IL6R receptor Activated 2.236 6.06E-04 7 
MKNK1 kinase Activated 2.714 6.47E-04 11 
Table 4.2 Upstream regulator analysis. Differentially expressed genes were analyzed with the Ingenuity 
Pathway Analysis tool (IPA) performing an upstream regulator analysis, in order to identify possible 
alterations in the activity of master regulators of gene expression, that may be responsible for the 
changes observed in the experimental dataset. The table shows the most promising master regulators 
resulting from the analysis, with the relative p-value and number of targets modulated. Cut-off: Z= ±1. 
In green, regulators that are potentially strongly inhibited (Z score < -2); in red, regulators that are 
potentially strongly activated (Z score > 2). In bold, master regulator selected for further studies. 
Among the potential candidates, we focused on TCF7L2 (Table 4.2), an essential effector of the 
Wnt pathway that can also work in a Wnt-independent manner and promote oligodendrocyte 
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maturation (Hammond et al., 2015). Indeed, the analysis showed that the down-regulation of 
27 genes in our experimental dataset could be related to an inhibition of the TCF7L2 signaling 
(Fig. 4.11), as suggested by the low Z score (-5.186).  
 
Figure 4.11 MiR-125a-3p over-expression represses TCF7L2 signaling in OPCs. Genes related to 
TCF7L2 signaling in the experimental dataset. The scheme shows that the alteration of multiple genes 
after miR-125a-3p over-expression could be related to TCF7L2 signaling inhibition. Blue arrows represent 
negative interaction (leads to inhibition). Green shapes represent transcripts down-regulated in the 
experimental dataset. Green intensity directly correlates to the entity of the down-regulation. 
Based on this result and the opposite role that TCF7L2 can exert on oligodendrocyte maturation 
depending on its interaction partners, we hypothesized that the over-expression of miR-125a-
3p lead to Wnt signaling over-activation and to an increased association of β-catenin to TCF7L2, 
preventing its pro-myelinating Wnt-independent effect. To assess this hypothesis, we utilized a 
______________________________________________________________________________________________________RESULTS 
86 
 
pathway focused “Wnt signaling targets” array, which simultaneously profiles the expression of 
84 key genes responsive to WNT signal transduction (see Appendix C). After the over-
expression of miR-125a-3p, expression changes were detected in 26 of 84 genes (Fig. 4.12a). 
The 14 down-regulated genes were: Bmp4, Enpp2, Fosl1, Fst, Jag1, Lrp1, Met, Mmp2, Nrp1, 
Pdgfra, Sox2, Tcf7l1, Tcf7l2 and Tle1. The 12 up-regulated genes were: Abcb1a, Birc5, Cdh1, 
Ctgf, Dlk1, Egr1, Fn1, Gja1, Klf5, Smo, Tcf7 and Wnt3a. Changes in the expression levels of 
Wnt3a, a Wnt ligand, and of Tcf7, Tcf7l1, Tcf7l2, downstream nuclear factors of the Wnt 
signaling, suggest an over-activation of the Wnt pathway (Fig. 4.12b). 
Figure 4.12 Evaluation of Wnt targets expression after miR-125a-3p over-expression in OPCs. (a) 
Scatter plot comparing the normalized expression of each genes of the “Wnt targets” PCR array between 
the two groups (miR-125a-3p over-expression vs negative control). Red asterisks represent genes up-
regulated, green asterisks represent genes down-regulated. Black asterisks in the central line indicate 
unchanged gene expression. Cut-off = ±1.3 (b) Histogram shows changes in the expression of Tcf7, 
Tcf7l1 and Tcf7l2 after mir-125a-3p over-expression in OPCs (control set to ±1).  
The Gene Ontology-based analysis allowed us to identify common biological processes and 
functions for differentially expressed genes, suggesting that miR-125a-3p can take part in their 
regulation. Biological processes resulting from the gene-ontology-based analysis are reported 
in Table 4.3. The most significant biological process, “Role of cell-cell and ECM-cell interactions 
in oligodendrocyte differentiation and myelination”, was studied more in detail by means of a 
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specific PCR array, “Extracellular Matrix & Adhesion Molecules”, that simultaneously profiles the 
expression of 84 genes important for cell-cell and cell-matrix interactions (see Appendix D). In 
the “Extracellular Matrix & Adhesion Molecules” array, after miR-125a-3p over-expression, 
expression changes were detected in 41 of 84 genes (Fig. 4.13a). The 12 down-regulated genes 
were: Col3a1, Fn1, Thbs2, Entpd1, Fbln1, Sparc, Icam1, Timp1, Thbs1, Col1a1, Spp1 and Lamb2. 
The 29 up-regulated genes were: Adamts1, Adamts5, Catna1, Cdh1, Cdh2, Cdh4, Cntn1, Col2a1, 
Col4a1, Col4a3, Itga3, Itga4, Itga5, Itga9, Itgav, Itgb1, Itgb3, Lama2, Lamc1, Mmp10, Mmp11, 
Mmp15, Mmp2, Mmp9, Spock1, Syt1, Tgfbi, Timp3 and Vcan. 
Biological Process Total 
FDR 
p-value 
N°of  
targets 
Targets in the dataset 
Role of cell-cell and ECM-cell 
interactions in oligodendrocyte 
differentiation and myelination 
34 9.1E-05 9 
Claudin-11, PLP1, Connexin 43, 
Connexin 26, Reticulon 4, MAG, GJC3, 
Myelin basic protein, Connexin 32 
Cell adhesion_Gap junctions 30 1.6E-02 6 
PKC, Connexin 43, Connexin 31, 
Connexin 26, Connexin 32, Tubulin beta 
Role of Thyroid hormone in 
regulation of oligodendrocyte 
differentiation 
48 2.6E-02 7 
TR-beta, PLP1, p73, MOG, MAG, Myelin 
basic protein, OATP-A 
ATM / ATR regulation of G2 / M 
checkpoint 
26 3.1E-02 5 
Chk1, Chk2, Cyclin B, Claspin, GADD45 
beta 
Substance P-stimulated expression 
of proinflammatory cytokines via 
MAPKs 
43 3.9E-02 6 
PKC-delta, PLC-beta, Substance P 
extracellular region, CCL13, c-Jun, GRO-
2 
Oxidative stress_Activation of 
NADPH oxidase 
59 3.9E-02 7 
PKC, PKC-delta, p47-phox, PLC-beta, 
p22-phox, TRIO, Rac2 
HDL-mediated reverse cholesterol 
transport 
44 3.9E-02 6 
Pre beta-1 HDL, Nascent HDL, Large 
apoE-rich HDL, APOA1, PLTP, APOE 
Cytoskeleton remodeling 102 5.3E-02 9 
Fibronectin, MyHC, MYLK1, MLCK, 
Collagen I, TGF-beta receptor type I, 
TRIO, c-Jun, LIMK2 
Table 4.3 Ontology-based clusterization with Metacore. The software Metacore was used to perform 
an ontology-based analysis of the 1067 differentially expressed genes, in order to identify common 
biological processes and functions. In table are reported the resulting more significant biological 
processes and the relative associated genes from the experimental dataset. In bold, biological processes 
selected for further studies. 
Differentially expressed genes of interest were divided in two groups: adhesion molecules and 
ECM proteins. Among adhesion molecules, miR-125a-3p over-expression globally reduced the 
expression of connectin 1 (Cntn1), integrins (Itg) and laminins (Lam) (Fig. 4.13b). Among ECM 
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proteins, we observed alterations in the expression of disintegrin and metalloproteinases 
(ADAMTS) remodeling enzymes (Fig. 4.13c) and their inhibitors (TIMP). 
 
Figure 4.13 Evaluation of Extracellular Matrix & Adhesion Molecules after miR-125a-3p over-
expression in OPCs. (a) Scatter plot comparing the normalized expression of each genes of the 
“Extracellular Matrix & Adhesion Molecules” PCR array between the two groups (miR-125a-3p over-
expression vs negative control). Red asterisks represent genes up-regulated, green asterisks represent 
genes down-regulated. Black asterisks in the central line indicate unchanged gene expression. Cut-off = 
±1.3 (b) Histogram shows changes in the expression of selected adhesion molecules (control set to ±1). 
(c) Histogram shows changes in the expression of selected ECM proteins (control set to ±1). 
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5.1 MiR-125a-3p over-expression in OPCs represents a new pathogenetic 
mechanism that can contribute to re-myelination failure following a 
demyelinating injury 
Several papers have described the miR-125 family (composed by miR-125a and 125b) 
as one of the most important for its implication in cancer (Sun et al., 2013). Only recently, the 
role of miR-125a has been investigated also under physiological settings, when a fine balance 
between proliferation and differentiation is responsible for cell lineage commitment. Despite 
previous studies demonstrating its presence in oligodendrocytes, with higher abundance of the 
-3p compared to the -5p strand (Jovicic et al., 2013), no functional roles for this miRNA in these 
cells was demonstrated yet. Here, we describe miR-125a-3p as a new regulator of 
oligodendroglial differentiation and myelination and we propose that its pathological up-
regulation could represent a new pathogenetic mechanism involved in re-myelination failure.  
Our gene ontology based study showed that several of the predicted target mRNAs of 
this miRNA are involved in nervous system development, with higher enrichment in glial cell 
differentiation, myelination, axon ensheathment and oligodendrocyte differentiation (see Fig. 
1), suggesting that miR-125a-3p may have a primary role in the regulation of these processes. 
We also showed that, both in rodents and humans, miR-125a-3p is more abundantly expressed 
in CNS with respect to peripheral tissues, with a higher expression in neurons and 
oligodendrocytes. Our expression studies during brain development showed very high levels of 
miR-125a-3p at embryonic day E14, mainly in neural precursors (see Fig 2). This is in line with 
previous literature data demonstrating that miR-125a directly binds SMAD4, a key regulator of 
pluripotent stem cell lineage commitment, thus potentiating early neural specification (Boissart 
et al., 2012). Moreover, during postnatal life, SMAD4 and its cascade inhibit oligodendrogenesis 
by inducing the Id and Hes genes and by repressing Olig1 and Olig2 (Cheng et al., 2007). 
Interestingly, by means of in situ hybridization, we found that miR-125a-3p is expressed 
throughout post-natal age in Olig2+ oligodendrocytes, suggesting that, in these cells, may be 
necessary for silencing SMAD4, to promote the expression of these genes and the subsequent 
oligodendroglial specification.  
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Several miRNAs have been demonstrated to regulate the transition from neural stem cells to 
mature oligodendrocytes. Indeed, as OPCs differentiate, the levels of several miRNAs, including 
miR-138, -219 and -338, increase and promote maturation through the inhibition of repressors 
of oligodendrocytes differentiation, such as Hes5, Sox6, Foxj3, and of genes that promote OPC 
proliferation, such as Fgfr2 and Pdgfrα (Dugas et al., 2010; Zhao et al., 2010a). In line with the 
hypothesis of the modulation of early targets, during in vitro OPC differentiation miR-125a-3p 
is progressively up-regulated (Fig. 2f). In situ hybridization studies showed that almost all 
mature oligodendrocytes, positive for CC1, express miR-125a-3p, whereas only a subset of 
NG2+ cells express it (Fig. 2e), suggesting a role in the repression of early genes when 
oligodendrocytes become mature and/or myelinating.  
Recent literature has demonstrated that a single miRNA can regulate hundreds of 
transcripts, thus having a very broad array of functional consequences (Wu et al., 2007). Thus, 
integration of the information on multiple targets of a given miRNA can shed light on very 
complex regulatory networks like those of transcription factors. In this respect, our data on the 
role of miR-125a-3p on OPCs maturation under “strong” or “mild” differentiation paradigms 
unveil that myelination may be regulated in different ways even by the same miRNA depending 
upon distinct pathophysiological conditions. Specifically, to understand the effect of miR-125a-
3p on OPC differentiation in vitro, we took advantage of 4 different markers that identify 4 
distinct sequential stages of OPC differentiation, namely: GPR17, O4, MAP1B, and MBP (Fig. 3). 
Among them, GPR17 is an oligodendroglial marker expressed in early OPCs up to the stage of 
immature pre-oligodendrocytes (Fumagalli et al., 2011) and widely adopted to specifically label 
OPCs at an intermediate differentiation stage partially overlapping with O4 (Fig. 3; Boda et al., 
2011; Crociara et al., 2013; Fumagalli et al., 2015). O4 is instead a well-established marker of 
immature oligodendrocytes (Franke et al., 2013). MAP1B is the major microtubule associated 
protein found in microtubules early during development (Wu et al., 2001). In oligodendrocytes, 
MAP1B expression is slightly delayed compared to O4 and immediately precedes 
morphological differentiation, after which MAP1B is strongly down-regulated (Vouyiouklis and 
Brophy, 1993). Finally, MBP is known to label mature oligodendrocytes, being a protein 
associated to myelin (Baumann et al., 2001). When miR-125a-3p was overexpressed by mimic 
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transfection in the presence of T3 (“strong” differentiation protocol), the block of terminal 
maturation was accompanied by a strong reduction of MAP1B and MBP expression, whereas 
earlier markers were not affected. However, when miR-125a-3p overexpression was performed 
using the “mild” differentiation protocol (i.e., in the absence of T3), OPCs proceeded slower 
along their lineage and late antigens were not visible, but the number of earlier GPR17+ and 
MAP1B+ precursors was diminished, to suggest that, under these conditions, miR-125a-3p can 
regulate OPC maturation not only downstream but also upstream to GPR17.  
Globally, our in vitro data suggest that when miR-125a-3p levels are high, oligodendrocyte 
maturation is delayed, and this could explain the high expression levels found during 
embryogenesis, to suggest that miR-125a-3p may, at the same time, promote neural 
specification and prevent the untimely expression of genes necessary for oligodendrocyte 
commitment/maturation and the subsequent myelination process that, indeed, does not take 
place at this stage. Moreover, these findings show that the biological role of miR-125a-3p 
changes depending on the developmental stage, and that, from embryonic life to adulthood, 
its expression moves from brain ventricles to parenchyma up to neurons of the cerebral cortex, 
where it is likely to repress the expression of non-neuronal genes. 
Recently, several studies have correlated alterations of miRNA homeostasis to the 
development of pathological conditions, typical of neurodegenerative diseases, showing that 
miRNAs can influence disease pathogenesis (Bicchi et al., 2013). Our in silico and in vitro data 
suggested that alterations in miR-125a-3p levels may have a high relevance in demyelinating 
diseases such as multiple sclerosis, in which extensive re-myelination failure is responsible of 
the lesion formation and the subsequent neurological outcomes. To investigate the role played 
by miR-125a-3p both during demyelination process and re-myelination attempts, we evaluated 
its expression in two different mouse models of toxic de-myelination. In the first model, the 
toxicant cuprizone was supplemented to the diet and administered to animals for five weeks to 
induce de-myelination of the corpus callosum. During the de-myelination phase, we observed 
a significant up-regulation of miR-125a-3p after 3 weeks of cuprizone administration (see Fig. 
4.5). At this time point, mature oligodendrocytes are almost completely depleted by the 
toxicant, whereas, NG2-positive precursors start to proliferate in response to damage and 
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migrate towards the corpus callosum (Gudi et al., 2014), suggesting that miR-125a-3p up-
regulation take place in these cells. In the cuprizone model, re-myelination is very robust and 
starts directly after demyelination is complete, regardless if cuprizone is further administered 
to animals (Gudi et al., 2014). Thus, the persistent up-regulation of miR-125a-3p observed after 
cuprizone withdrawal could be partially explained by the increase in the number of mature 
oligodendrocytes, that, as we showed (see Fig. 4.2), normally express higher levels of miR-125a-
3p compared to OPCs.  
To further demonstrate the link between miR-125a-3p up-regulation and de-myelinating 
conditions we took advantage of organotypic cerebellar slices, a widely used model for study 
de-myelination and re-myelination processes (Zhang et al., 2011). In this toxic model, the 
detergent lysolecithin is used to produce local de-myelination. As in the cuprizone model, OPCs 
respond to damage and start the re-myelination process, but in a faster and more reproducible 
way (Tan et al., 2017). Interestingly, at 3-days post-lesion, we found a significant up-regulation 
of miR-125a-3p expression in cerebellar slices treated with lysolecithin (see Fig. 4.6), supporting 
our hypothesis. 
Globally, our data in different models of de-myelination, show that OPCs up-regulate miR-
125a-3p in response to a de-myelinating injury, suggesting that this alteration could represent 
a hallmark of de-myelination damage, however, this alteration is not sufficient to counteract 
the spontaneous re-myelination typical of these models.  
To overcome such spontaneous re-myelination and assess if miR-125a-3p up-regulation may 
have a role in a pathological context, we over-expressed it by means of lentiviral infection in 
the white matter of mice following lysolecithin induced de-myelination. Interestingly, we found 
that miR-125a-3p infection maintained oligodendrocytes in the NG2-positive precursor stage 
(see Fig. 4.4), in line with a delay of their maturation and of the subsequent re-myelination 
process, suggesting that miR-125a-3p could represent a new pathogenetic mechanism that 
negatively regulate re-myelination. Other studies have recently shown how the modulation of 
a single miRNA can influence re-myelination efficacy. For example, it has been shown that 
infusion of miR-219 mimic promotes, whereas its inhibition represses, in vivo re-myelination 
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after lysolecithin-induced demyelinating injury (Wang et al., 2017), likely modulating the 
expression of multiple inhibitors of myelination. 
The identification of miR-125a-3p as a modulator of oligodendrocyte differentiation and 
myelination provide new findings in the complex regulation of de/re-myelination processes. 
Moreover, results from this study suggest that an antago-miRNA specific for miR-125a-3p may 
help in promoting oligodendrocyte maturation in diseases characterized by impaired myelin 
repair.  
5.2 MiR-125a-3p controls oligodendrocyte maturation and myelination acting on 
multiple pathways 
In the literature, several transcripts involved in pathways eventually linked to 
myelination have been so far identified as direct targets of miR-125a-3p. By using the Ingenuity 
Pathway Analysis tool, we connected several of these players to each other, building a model 
for the synergic regulation of MBP and myelination (see Fig. 4.9). Among these players, Fyn-
kinase plays important roles in neuronal functions, myelination, oligodendrocytes formation 
and cytoskeletal rearrangements (Klein et al., 2002). NRG1 is a potent chemoattractant that 
selectively regulates OPC migration during early CNS development stages of CNS through 
interaction with the ErbB4 receptor (Ortega et al., 2012). In line with the prediction of our IPA 
analysis, overexpression of miR-125a-3p resulted in a reduction of Fyn, NRG1 and MAP1B (see 
Fig. 4.9). It is worth to note that despite a striking effect on MBP expression, the reduction of 
these genes was quantitatively smaller, supporting the hypothesis that the mechanism of action 
consists in a fine modulation of a network of genes. Moreover, miRNAs do not necessarily 
degrade their target mRNAs, but they can also impair their translation into protein (Pasquinelli 
et al., 2012), thus, the downregulation observed by qRT-PCR may not fully reflect the observed 
functional effect. These data are also consistent with the previous demonstration that the 
mRNAs of both MAP1B and MBP are stabilized by the RNA-binding protein QKI, which is, in 
turn, regulated by Fyn-Kinase. Lack of Fyn-kinase, as detected after mimic transfection, leads to 
failure of MBP to incorporate into myelin (White et al., 2008). Moreover, Fyn activation is 
mediated by phosphorylation of a tyrosine residue (Y420), which, in turn, depends on the 
interaction between NRG1 (which is downregulated after mimic transfection) and its receptor 
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ERBB4 (Bjarnadottir et al., 2007). All these data support the hypothesis that miR-125a-3p 
synergistically inhibits different mechanisms that normally promote the expression of myelin 
genes. Interestingly, the miRNA prediction tool myMir reported that also GPR17 is a putative 
target of miR-125a-3p, suggesting that it could be regulated by miR-125a-3p during OPC 
maturation. Nevertheless, in our studies we were not able to demonstrate a direct interaction 
between the miRNA and GPR17 transcript, suggesting that the effect on GPR17 expression 
could be indirect. 
To identify new mechanisms altered by miR-125a-3p during OPC maturation, we performed a 
transcriptomic analysis after its over-expression using the “strong” differentiation protocol (see 
Fig. 4.10). Interestingly, by matching the down-regulated genes in the dataset with the top 50 
up-regulated genes during OPC maturation (Dugas et al., 2006), we found 25 genes down-
regulated, confirming our data showing that miR-125a-3p exerts a strong negative effect on 
OPC maturation. 
Differentially expressed genes were analyzed with two complementary approaches to identify 
common pathways and biological processes.  
A first pathway-based analysis, performed with IPA tool, suggested that the expression changes 
of several genes in the dataset may be related to TCF7L2 signaling inactivation (see Fig. 4.11). 
TCF7L2 is an important effector of the Wnt/β-catenin pathway, but, as recently shown, it can 
also act in a Wnt-independent manner by interacting with other co-factors (Kaiso and Sox10), 
to promote oligodendrocyte maturation (Zhao et al., 2016). Since it is widely known that 
constitutive activation of Wnt/b-catenin inhibits oligodendrocyte maturation (Hammond et al., 
2015), we hypothesized that miR-125a-3p over-expression could induce an over-activation of 
the Wnt pathway, which, in turn, leads to an increased association of β-catenin to TCF7L2, 
preventing its pro-myelinating effects. Our PCR array analysis on Wnt signaling after miR-125a-
3p over-expression in OPCs revealed an up-regulation of the Wnt ligand Wnt3a coupled to up-
regulation of Tcf7 and down-regulation of Tcf7l1 and Tcf7l2 downstream effectors, expression 
changes that have been previously associated to Wnt-signaling stimulation (Kuwahara et al., 
2014), supporting our hypothesis. 
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A second ontology-based approach allowed us to identify common biological process for 
differentially expressed genes. The analysis revealed that miR-125a-3p can modulate several 
processes related to oligodendrocyte maturation and myelination, such as “adhesion molecules 
and ECM proteins”, “gap junctions” and “thyroid hormone signaling”. PCR array specific for 
“Extracellular Matrix & Adhesion Molecules” was used to simultaneously profile the expression 
of 84 genes involved in cell-cell and cell-matrix interactions. Our data showed that miR-125a-
3p over-expression in OPCs altered the expression of several class of ECM and adhesion 
molecules, such as contactin (cntn), collagens (Col), integrins (Itg), laminins (Lam) and 
disintegrin and metalloproteinases (Adamts). Despite some of these class of molecules may 
have a dispensable role during OPC in vitro maturation, several reports in literature showed 
that such alterations are usually associated to dysmyelinating conditions, suggesting that our 
data could have a high relevance in vivo. For example, it has been reported that disruption of 
integrin-ECM connection leads to aberrant process and myelin sheath formation (Olsen et al., 
2005). Moreover, antibodies blocking β1-integrin reduce the ability of OPCs to extend their 
processes in vitro (Buttery and Ffrench-Constant, 1999). Interestingly, one of the downstream 
mechanisms that mediate integrin effects on OPC morphological differentiation is the activation 
of the Fyn kinase, which, in turn, regulates several downstream signaling, such as Rac1 and 
RhoA (O’Meara et al., 2011), suggesting that, also in this case, miR-125a-3p can influence 
several actors of a common pathway. Other reports have shown that β1-integrin can also form 
a functional signaling unit by associating to contactin 1 (cntn1) and regulate Fyn activation by 
controlling its phosphorylation state (Laursen et al., 2009). These data suggest that miR-125a-
3p over-expression can not only directly influence Fyn expression, but also indirectly control its 
activity by modulation of upstream signaling molecules.  
Down-regulation of Adamts1 and Adamts5, and their inhibitor Timp3, as well as up-regulation 
of Col1a1 and Col3a1, were instead found in human MS active lesions (Haddock et al., 2006; 
Mohan et al., 2010), suggesting that miR-125a-3p over-expression can recapitulate in OPCs 
some typical pathological features that they acquire in a demyelinating milieu.  
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Considering the mechanism of action of miRNAs, that not necessarily lead to the degradation 
of target mRNAs, a future proteomic analysis after miR-125a-3p over-expression will help to 
interpret and strengthen these transcriptomic data. 
Globally, these data suggest that miR-125a-3p can modulate different aspects of OPC 
development, playing an essential role in cell differentiation, myelination and dysmyelination. 
The identification of new miR-125a-3p direct targets will allow not only to clarify the networks 
that orchestrate these mechanisms, but also to identify new pharmacological targets to foster 
re-myelination processes in diseases characterized by myelination defects. 
5.3 MiR-125a-3p alteration in the CSF from human MS patients correlates with 
disease activity 
Reports from oncology, cardiovascular research and infectivology have demonstrated 
the potential diagnostic and prognostic significance of miRNAs passively leaked or actively 
released from cells into biological fluids including circulating blood and CSF (Corsten et al., 
2010), either contributing to disease pathogenesis or reflecting response to treatment. Living 
neurons, but also oligodendrocytes and other CNS cells secrete miRNAs into the extracellular 
space packaged in exosomes or microvesicles (Saman et al., 2012; Verderio et al., 2012). Recent 
evidence support that miRNAs are altered in bodily fluids in Parkinson’s and Alzheimer’s 
Disease (Gui et al., 2015), suggesting that their release does reflect not only activation of 
immune cells, but also the undergoing neurodegenerative process.  
In a previous study, the -5p arm of miR-125a was found to act as a key regulator of brain 
endothelial integrity and its levels to be increased in MS brain lesions as compared to 
surrounding normal appearing white matter (Reijerkerk et al., 2013). Coherently, treatment of 
MS patients with the anti-VLA4 monoclonal antibody (Tysabri) that inhibits inflammatory cell 
migration to the brain parenchyma and thus favours endothelial integrity, results in decreased 
blood levels of miR-125a-5p (Munoz-Culla et al., 2014). However, up to the present study, 
changes of the -3p arm of this miRNA had not been investigated. Here we show that miR-125a-
3p is up-regulated in the CSF of relapsing MS patients compared to control subjects. This 
alteration was specific for MS, since it was not found in Alzheimer's disease patients.  
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This increase could be explained by passive release of miR-125a-3p from neural cells such as 
neurons or oligodendrocytes undergoing destruction in active MS patients. We cannot 
obviously exclude that the aberrant presence of this miRNA in CSF could also reflect the 
inflammation state of the CNS during the relapsing-remitting phase of the disease (Romme 
Christensen et al., 2014), since previous reports have demonstrated the role of miR-125a in 
immune cells activation (Kumar et al., 2014).  
The transposition of the in vitro and in vivo results presented in this thesis to human MS 
subjects should of course take in account the high heterogeneity of OPCs, that do not 
necessarily behave in the same exact way. However, our data showing increased levels of miR-
125a-3p in the CSF of MS patients in the relapsing phase could serve as a basis for further 
studies on larger cohort of patients to validate miR-125a-3p as a biomarker for different MS 
stages, providing a previously unrecognized venue for medical interventions. 
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APPENDIX A 
AD     Alzheimer’s Disease 
AIDs     Auto-Immune Diseases 
BPs     Biological Processes 
CC     Corpus Callosum 
CX     Cerebral Cortex 
CSF     CerebroSpinal Fluid 
DIG     Digoxigenin 
DIV     Days In vitro 
DPL     Days Post Lesion 
ECM     ExtraCellular Matrix 
FDR     False Discovery Rate 
GBM     Glioblastoma Multiforme 
GO     Gene Ontology 
HDACs     Histone Deacetylase 
IPA     Ingenuity Pathway Analysis 
LNA     Locked Nucleic Acid 
LPC     Lysolecithin 
LV     Lentivirus 
MCI     Mild Cognitive Impairment 
MNs     Motoneurons 
MRI     Magnetic Resonance Imaging 
MS     Multiple Sclerosis 
NDs     Neurodegenerative Diseases 
OPCs     Oligodendrocyte Precursor Cells 
PD     Parkinson’s Disease 
PP-MS     Primary Progressive Multiple Sclerosis 
RISC     RNA-Induced Silencing Complex 
RR-MS     Relapsing Remitting Multiple Sclerosis 
SP-MS     Secondary Progressive Multiple Sclerosis  
TLR     Toll-Like Receptor  
UTR     UnTranslated Region 
VZ     Ventricular Zone 
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APPENDIX B 
Bioinformatic tools: 
NCBI     http://www.ncbi.nlm.nih.gov/ 
BLAST    http://www.ncbi.nlm.nih.gov/blast 
STRING    https://string-db.org/ 
Gene Ontology   http://www.geneontology.org/ 
miRanda    http://www.microrna.org 
miRwalk 2.0 http://zmf.umm.uni-heidelberg.de 
/apps/zmf/mirwalk2/ 
MyMir     http://www.itb.cnr.it/micro/ 
RNA22 v2    https://cm.jefferson.edu/rna22/Interactive/ 
 
 
Software: 
IPA® (Qiagen)   www.qiagen.com/ingenuity 
Metacore™    https://portal.genego.com/ 
ClustalX 2.1    http://www.clustal.org/clustal2/ 
ImageJ    https://imagej.nih.gov/ij/ 
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APPENDIX C 
RT² Profiler™ PCR Array Rat WNT Signaling Targets (PARN-243Z) 
Symbol Description GeneBank 
Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A NM_133401 
Ahr Aryl hydrocarbon receptor NM_013149 
Angptl4 Angiopoietin-like 4 NM_199115 
Antxr1 Anthrax toxin receptor 1 NM_001044249 
Axin2 Axin 2 NM_024355 
Bglap Bone gamma-carboxyglutamate (gla) protein NM_013414 
Birc5 Baculoviral IAP repeat-containing 5 NM_022274 
Bmp4 Bone morphogenetic protein 4 NM_012827 
Btrc Beta-transducin repeat containing NM_001007148 
Cacna2d3 Calcium channel, voltage-dependent, alpha2/delta subunit 3 NM_175595 
Ccnd1 Cyclin D1 NM_171992 
Ccnd2 Cyclin D2 NM_022267 
Cd44 Cd44 molecule NM_012924 
Cdh1 Cadherin 1 NM_031334 
Cdkn2a Cyclin-dependent kinase inhibitor 2A NM_031550 
Cdon Cdon homolog (mouse) NM_017358 
Cebpd CCAAT/enhancer binding protein (C/EBP), delta NM_013154 
Ctgf Connective tissue growth factor NM_022266 
Cubn Cubilin (intrinsic factor-cobalamin receptor) NM_053332 
Dab2 Disabled homolog 2 (Drosophila) NM_024159 
Dkk1 Dickkopf homolog 1 (Xenopus laevis) NM_001106350 
Dlk1 Delta-like 1 homolog (Drosophila) NM_053744 
Dpp10 Dipeptidylpeptidase 10 NM_001012205 
Efnb1 Ephrin B1 NM_017089 
Egfr Epidermal growth factor receptor NM_031507 
Egr1 Early growth response 1 NM_012551 
Enpp2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 NM_057104 
Ets2 V-ets erythroblastosis virus E26 oncogene homolog 2 NM_001107107 
Fgf20 Fibroblast growth factor 20 NM_023961 
Fgf4 Fibroblast growth factor 4 NM_053809 
Fgf7 Fibroblast growth factor 7 NM_022182 
Fgf9 Fibroblast growth factor 9 NM_012952 
Fn1 Fibronectin 1 NM_019143 
Fosl1 Fos-like antigen 1 NM_012953 
Fst Follistatin NM_012561 
Gdf5 Growth differentiation factor 5 XM_001066344 
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RT² Profiler™ PCR Array Rat WNT Signaling Targets (PARN-243Z) 
Gdnf Glial cell derived neurotrophic factor NM_019139 
Gja1 Gap junction protein, alpha 1 NM_012567 
Id2 Inhibitor of DNA binding 2 NM_013060 
Igf1 Insulin-like growth factor 1 NM_178866 
Igf2 Insulin-like growth factor 2 NM_031511 
Il6 Interleukin 6 NM_012589 
Irs1 Insulin receptor substrate 1 NM_012969 
Jag1 Jagged 1 NM_019147 
Klf5 Kruppel-like factor 5 NM_053394 
Lef1 Lymphoid enhancer binding factor 1 NM_130429 
Lrp1 Low density lipoprotein-related protein 1 NM_001130490 
Met Met proto-oncogene NM_031517 
Mmp2 Matrix metallopeptidase 2 NM_031054 
Mmp7 Matrix metallopeptidase 7 NM_012864 
Mmp9 Matrix metallopeptidase 9 NM_031055 
Myc Myelocytomatosis oncogene NM_012603 
Nanog Nanog homeobox NM_001100781 
Nrcam Neuronal cell adhesion molecule NM_013150 
Nrp1 Neuropilin 1 NM_145098 
Ntrk2 Neurotrophic tyrosine kinase, receptor, type 2 NM_012731 
Pdgfra Platelet derived growth factor receptor, alpha NM_012802 
Pitx2 Paired-like homeodomain 2 NM_019334 
Plaur Plasminogen activator, urokinase receptor NM_017350 
Pou5f1 POU class 5 homeobox 1 NM_001009178 
Ppap2b Phosphatidic acid phosphatase type 2B NM_138905 
Ppard Peroxisome proliferator-activated receptor delta NM_013141 
Ptch1 Patched homolog 1 (Drosophila) NM_053566 
Ptgs2 Prostaglandin-endoperoxide synthase 2 NM_017232 
Runx2 Runt-related transcription factor 2 NM_053470 
Sfrp2 Secreted frizzled-related protein 2 NM_001100700 
Six1 SIX homeobox 1 NM_053759 
Smo Smoothened homolog (Drosophila) NM_012807 
Sox2 SRY (sex determining region Y)-box 2 NM_001109181 
Sox9 SRY-box containing gene 9 XM_001081628 
T T, brachyury homolog (mouse) NM_001106209 
Tcf7l1 Transcription factor 3 NM_001107865 
Tcf4 Transcription factor 4 NM_053369 
Tcf7 Transcription factor 7 (T-cell specific, HMG-box) XM_006220666 
Tcf7l2 Transcription factor 7-like 2 (T-cell specific, HMG-box) NM_001191052 
Tgfb3 Transforming growth factor, beta 3 NM_013174 
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RT² Profiler™ PCR Array Rat WNT Signaling Targets (PARN-243Z) 
Tle1 Transducin-like enhancer of split 1 NM_001173433 
Twist1 Twist homolog 1 (Drosophila) NM_053530 
Vegfa Vascular endothelial growth factor A NM_031836 
Wisp1 WNT1 inducible signaling pathway protein 1 NM_031716 
Wisp2 WNT1 inducible signaling pathway protein 2 NM_031590 
Wnt3a Wingless-type MMTV integration site family, member 3A NM_001107005 
Wnt5a Wingless-type MMTV integration site family, member 5A NM_022631 
Wnt9a Wingless-type MMTV integration site family, member 9A NM_001105783 
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APPENDIX D 
RT² Profiler™ PCR Array Rat Extracellular Matrix & Adhesion Molecules (PARN-013Z) 
Symbol Description GeneBank 
Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 NM_024400 
Adamts2 ADAM metallopeptidase with thrombospondin type 1 motif, 2 NM_001137622 
Adamts5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 NM_198761 
Adamts8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 NM_001106811 
Catna1 Catenin (cadherin associated protein), alpha 1 NM_001007145 
Cd44 Cd44 molecule NM_012924 
Cdh1 Cadherin 1 NM_031334 
Cdh2 Cadherin 2 NM_031333 
Cdh3 Cadherin 3 NM_053938 
Cdh4 Cadherin 4 XM_001061943 
Cntn1 Contactin 1 NM_057118 
Col1a1 Collagen, type I, alpha 1 NM_053304 
Col2a1 Collagen, type II, alpha 1 NM_012929 
Col3a1 Collagen, type III, alpha 1 NM_032085 
Col4a1 Collagen, type IV, alpha 1 NM_001135009 
Col4a2 Collagen, type IV, alpha 2 XM_001076134 
Col4a3 Collagen, type IV, alpha 3 NM_001135759 
Col5a1 Collagen, type V, alpha 1 NM_134452 
Col6a1 Collagen, type VI, alpha 1 XM_215375 
Col8a1 Collagen, type VIII, alpha 1 NM_001107100 
Ctgf Connective tissue growth factor NM_022266 
Ctnna2 Catenin (cadherin associated protein), alpha 2 NM_001106598 
Ctnnb1 Catenin (cadherin associated protein), beta 1 NM_053357 
Ecm1 Extracellular matrix protein 1 NM_053882 
Emilin1 Elastin microfibril interfacer 1 NM_001106710 
Entpd1 Ectonucleoside triphosphate diphosphohydrolase 1 NM_022587 
Fbln1 Fibulin 1 NM_001127547 
Fn1 Fibronectin 1 NM_019143 
Hapln1 Hyaluronan and proteoglycan link protein 1 NM_019189 
Icam1 Intercellular adhesion molecule 1 NM_012967 
Itga2 Integrin, alpha 2 XM_345156 
Itga3 Integrin, alpha 3 NM_001108292 
Itga4 Integrin, alpha 4 NM_001107737 
Itga5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) NM_001108118 
Itgad Integrin, alpha D NM_031691 
Itgae Integrin, alpha E NM_031768 
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RT² Profiler™ PCR Array Rat Extracellular Matrix & Adhesion Molecules (PARN-013Z) 
Itgal Integrin, alpha L NM_001033998 
Itgam Integrin, alpha M NM_012711 
Itgav Integrin, alpha V NM_001106549 
Itgb1 Integrin, beta 1 NM_017022 
Itgb2 Integrin, beta 2 NM_001037780 
Itgb3 Integrin, beta 3 NM_153720 
Itgb4 Integrin, beta 4 NM_013180 
Lama1 Laminin, alpha 1 NM_001108237 
Lama2 Laminin, alpha 2 XM_008758643 
Lama3 Laminin, alpha 3 XM_003753026 
Lamb2 Laminin, beta 2 NM_012974 
Lamb3 Laminin, beta 3 NM_001100841 
Lamc1 Laminin, gamma 1 NM_053966 
Mmp10 Matrix metallopeptidase 10 NM_133514 
Mmp11 Matrix metallopeptidase 11 NM_012980 
Mmp12 Matrix metallopeptidase 12 NM_053963 
Mmp13 Matrix metallopeptidase 13 NM_133530 
Mmp14 Matrix metallopeptidase 14 (membrane-inserted) NM_031056 
Mmp15 Matrix metallopeptidase 15 NM_001106168 
Mmp16 Matrix metallopeptidase 16 NM_080776 
Mmp1 Matrix metallopeptidase 1a (interstitial collagenase) NM_001134530 
Mmp2 Matrix metallopeptidase 2 NM_031054 
Mmp3 Matrix metallopeptidase 3 NM_133523 
Mmp7 Matrix metallopeptidase 7 NM_012864 
Mmp8 Matrix metallopeptidase 8 NM_022221 
Mmp9 Matrix metallopeptidase 9 NM_031055 
Ncam1 Neural cell adhesion molecule 1 NM_031521 
Ncam2 Neural cell adhesion molecule 2 NM_203409 
Pecam1 Platelet/endothelial cell adhesion molecule 1 NM_031591 
Postn Periostin, osteoblast specific factor NM_001108550 
Sele Selectin E NM_138879 
Sell Selectin L NM_019177 
Selp Selectin P NM_013114 
Sgce Sarcoglycan, epsilon NM_001002023 
Sparc Secreted protein, acidic, cysteine-rich (osteonectin) NM_012656 
Spock1 Sparc/osteonectin, (testican) 1 NM_001271297 
Spp1 Secreted phosphoprotein 1 NM_012881 
Syt1 Synaptotagmin I NM_001033680 
Tgfbi Transforming growth factor, beta induced NM_053802 
Thbs1 Thrombospondin 1 NM_001013062 
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RT² Profiler™ PCR Array Rat Extracellular Matrix & Adhesion Molecules (PARN-013Z) 
Thbs2 Thrombospondin 2 NM_001169138 
Timp1 TIMP metallopeptidase inhibitor 1 NM_053819 
Timp2 TIMP metallopeptidase inhibitor 2 NM_021989 
Timp3 TIMP metallopeptidase inhibitor 3 NM_012886 
Tnc Tenascin C NM_053861 
Vcam1 Vascular cell adhesion molecule 1 NM_012889 
Vcan Versican NM_001170558 
Vtn Vitronectin NM_019156 
 
 
 
